https://trial.medpath.com/news/gsk-acquires-efimosfermin-for-1-2-billion-to-target-steatotic-liver-disease 2025-05-14T06:39:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-acquires-efimosfermin-for-1-2-billion-to-target-steatotic-liver-disease 2025-05-14T06:39:49+00:00 hourly 0.9 https://trial.medpath.com/news/intron-seeks-partners-to-repurpose-sal200-for-mrsa-nasal-decolonization-in-surgical-patients 2025-05-14T06:39:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/intron-seeks-partners-to-repurpose-sal200-for-mrsa-nasal-decolonization-in-surgical-patients 2025-05-14T06:39:30+00:00 hourly 0.9 https://trial.medpath.com/news/beam-therapeutics-to-present-updated-beam-101-data-from-17-sickle-cell-disease-patients-at-eha-2025 2025-05-14T06:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beam-therapeutics-to-present-updated-beam-101-data-from-17-sickle-cell-disease-patients-at-eha-2025 2025-05-14T06:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/titan-sgstm-stapler-shows-significant-reduction-in-post-operative-gerd-following-sleeve-gastrectomy 2025-05-14T06:09:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/titan-sgstm-stapler-shows-significant-reduction-in-post-operative-gerd-following-sleeve-gastrectomy 2025-05-14T06:09:42+00:00 hourly 0.9 https://trial.medpath.com/news/becton-dickinson-files-patent-infringement-lawsuit-against-baxter-over-infusion-pump-technology 2025-05-14T05:41:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/becton-dickinson-files-patent-infringement-lawsuit-against-baxter-over-infusion-pump-technology 2025-05-14T05:41:42+00:00 hourly 0.9 https://trial.medpath.com/news/novo-holdings-invests-in-schott-poonawalla-to-strengthen-injectable-drug-packaging-capabilities-in-india 2025-05-14T04:35:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-holdings-invests-in-schott-poonawalla-to-strengthen-injectable-drug-packaging-capabilities-in-india 2025-05-14T04:35:35+00:00 hourly 0.9 https://trial.medpath.com/news/exelixis-initiates-phase-1-trial-of-xb628-a-novel-bispecific-nk-cell-engager-for-advanced-solid-tumors 2025-05-14T04:35:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/exelixis-initiates-phase-1-trial-of-xb628-a-novel-bispecific-nk-cell-engager-for-advanced-solid-tumors 2025-05-14T04:35:29+00:00 hourly 0.9 https://trial.medpath.com/news/perfluorohexyloctane-shows-unprecedented-rapid-relief-for-dry-eye-disease-in-phase-4-study 2025-05-14T04:34:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/perfluorohexyloctane-shows-unprecedented-rapid-relief-for-dry-eye-disease-in-phase-4-study 2025-05-14T04:34:51+00:00 hourly 0.9 https://trial.medpath.com/news/nexalin-technology-strengthens-scientific-advisory-board-to-accelerate-alzheimer-s-research-with-novel-brain-stimulation-technology 2025-05-14T04:34:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nexalin-technology-strengthens-scientific-advisory-board-to-accelerate-alzheimer-s-research-with-novel-brain-stimulation-technology 2025-05-14T04:34:40+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-phase-2b-trial-for-adipose-derived-stem-cell-therapy-in-crohn-s-disease 2025-05-14T04:11:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-phase-2b-trial-for-adipose-derived-stem-cell-therapy-in-crohn-s-disease 2025-05-14T04:11:56+00:00 hourly 0.9 https://trial.medpath.com/news/adphc-partners-with-astrazeneca-to-combat-copd-in-abu-dhabi 2025-05-14T04:10:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adphc-partners-with-astrazeneca-to-combat-copd-in-abu-dhabi 2025-05-14T04:10:42+00:00 hourly 0.9 https://trial.medpath.com/news/cipla-targets-fy26-growth-with-glp-1-entry-and-peptide-pipeline-despite-revlimid-headwinds 2025-05-14T04:07:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cipla-targets-fy26-growth-with-glp-1-entry-and-peptide-pipeline-despite-revlimid-headwinds 2025-05-14T04:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/cellfe-and-made-scientific-partner-to-advance-non-viral-gene-editing-for-t-cell-therapies 2025-05-14T03:11:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cellfe-and-made-scientific-partner-to-advance-non-viral-gene-editing-for-t-cell-therapies 2025-05-14T03:11:23+00:00 hourly 0.9 https://trial.medpath.com/news/novel-compound-sana-shows-promise-in-phase-1-clinical-trial-for-obesity-treatment-through-unique-thermogenesis-mechanism 2025-05-14T02:41:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-compound-sana-shows-promise-in-phase-1-clinical-trial-for-obesity-treatment-through-unique-thermogenesis-mechanism 2025-05-14T02:41:23+00:00 hourly 0.9 https://trial.medpath.com/news/patient-centered-approaches-key-to-addressing-health-equity-and-disparities-experts-say 2025-05-14T02:41:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/patient-centered-approaches-key-to-addressing-health-equity-and-disparities-experts-say 2025-05-14T02:41:12+00:00 hourly 0.9 https://trial.medpath.com/news/api-appoints-dr-launa-aspeslet-as-chief-translational-officer-to-accelerate-canadian-life-sciences-commercialization 2025-05-14T02:40:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/api-appoints-dr-launa-aspeslet-as-chief-translational-officer-to-accelerate-canadian-life-sciences-commercialization 2025-05-14T02:40:29+00:00 hourly 0.9 https://trial.medpath.com/news/ats-2025-conference-to-showcase-groundbreaking-pulmonary-research-and-patient-centered-initiatives 2025-05-14T02:40:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ats-2025-conference-to-showcase-groundbreaking-pulmonary-research-and-patient-centered-initiatives 2025-05-14T02:40:04+00:00 hourly 0.9 https://trial.medpath.com/news/orchard-therapeutics-lenmeldy-shows-long-term-efficacy-in-treating-metachromatic-leukodystrophy-nejm-study-reveals 2025-05-14T01:41:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/orchard-therapeutics-lenmeldy-shows-long-term-efficacy-in-treating-metachromatic-leukodystrophy-nejm-study-reveals 2025-05-14T01:41:51+00:00 hourly 0.9 https://trial.medpath.com/news/hcw-biologics-secures-5-million-in-follow-on-financing-to-advance-immunotherapy-pipeline 2025-05-14T01:41:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hcw-biologics-secures-5-million-in-follow-on-financing-to-advance-immunotherapy-pipeline 2025-05-14T01:41:50+00:00 hourly 0.9 https://trial.medpath.com/news/ensysce-biosciences-secures-patent-for-novel-opioid-use-disorder-treatment-pf9001 2025-05-14T01:14:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ensysce-biosciences-secures-patent-for-novel-opioid-use-disorder-treatment-pf9001 2025-05-14T01:14:05+00:00 hourly 0.9 https://trial.medpath.com/news/altimmune-secures-100-million-credit-facility-to-advance-pemvidutide-development-for-mash-and-alcohol-related-disorders 2025-05-14T01:12:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/altimmune-secures-100-million-credit-facility-to-advance-pemvidutide-development-for-mash-and-alcohol-related-disorders 2025-05-14T01:12:58+00:00 hourly 0.9 https://trial.medpath.com/news/saint-louis-university-launches-phase-1-trial-for-investigational-west-nile-virus-vaccine 2025-05-14T00:37:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/saint-louis-university-launches-phase-1-trial-for-investigational-west-nile-virus-vaccine 2025-05-14T00:37:47+00:00 hourly 0.9 https://trial.medpath.com/news/meiragtx-unveils-breakthrough-gene-therapies-for-obesity-and-neurodegenerative-diseases-at-asgct-2025 2025-05-14T00:37:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/meiragtx-unveils-breakthrough-gene-therapies-for-obesity-and-neurodegenerative-diseases-at-asgct-2025 2025-05-14T00:37:05+00:00 hourly 0.9 https://trial.medpath.com/news/rgenta-therapeutics-unveils-rswitch-technology-for-precise-control-of-gene-therapy-expression 2025-05-14T00:36:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rgenta-therapeutics-unveils-rswitch-technology-for-precise-control-of-gene-therapy-expression 2025-05-14T00:36:39+00:00 hourly 0.9 https://trial.medpath.com/news/azenta-and-form-bio-partner-to-accelerate-aav-gene-therapy-development-with-ai-powered-analysis 2025-05-14T00:36:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/azenta-and-form-bio-partner-to-accelerate-aav-gene-therapy-development-with-ai-powered-analysis 2025-05-14T00:36:38+00:00 hourly 0.9 https://trial.medpath.com/news/circio-presents-enhanced-circvec-gene-therapy-data-showing-distinct-tissue-expression-patterns-at-asgct-2025 2025-05-14T00:36:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/circio-presents-enhanced-circvec-gene-therapy-data-showing-distinct-tissue-expression-patterns-at-asgct-2025 2025-05-14T00:36:34+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-warning-to-mayne-pharma-for-misleading-nextstellis-birth-control-safety-claims 2025-05-14T00:35:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-warning-to-mayne-pharma-for-misleading-nextstellis-birth-control-safety-claims 2025-05-14T00:35:54+00:00 hourly 0.9 https://trial.medpath.com/news/comend-and-odylia-therapeutics-form-strategic-partnership-to-transform-rare-disease-drug-development-through-patient-driven-platform 2025-05-14T00:34:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/comend-and-odylia-therapeutics-form-strategic-partnership-to-transform-rare-disease-drug-development-through-patient-driven-platform 2025-05-14T00:34:40+00:00 hourly 0.9 https://trial.medpath.com/news/avadel-pharmaceuticals-appoints-susan-rodriguez-as-chief-operating-officer-to-drive-lumryz-commercial-expansion 2025-05-14T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avadel-pharmaceuticals-appoints-susan-rodriguez-as-chief-operating-officer-to-drive-lumryz-commercial-expansion 2025-05-14T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/nhia-and-roche-expand-partnership-to-reduce-cancer-treatment-costs-in-nigeria 2025-05-14T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nhia-and-roche-expand-partnership-to-reduce-cancer-treatment-costs-in-nigeria 2025-05-14T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/stairmed-achieves-clinical-milestone-with-invasive-brain-computer-interface-system-in-amputee-patient 2025-05-14T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stairmed-achieves-clinical-milestone-with-invasive-brain-computer-interface-system-in-amputee-patient 2025-05-14T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/nanocarrier-technology-shows-promise-for-alzheimer-s-disease-treatment-by-overcoming-blood-brain-barrier 2025-05-14T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nanocarrier-technology-shows-promise-for-alzheimer-s-disease-treatment-by-overcoming-blood-brain-barrier 2025-05-14T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ethris-and-lonza-partner-to-develop-room-temperature-stable-mrna-respiratory-vaccines 2025-05-14T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ethris-and-lonza-partner-to-develop-room-temperature-stable-mrna-respiratory-vaccines 2025-05-14T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/adial-pharmaceuticals-receives-milestone-payment-as-adovate-launches-phase-1-trial-for-novel-asthma-therapy 2025-05-13T23:09:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adial-pharmaceuticals-receives-milestone-payment-as-adovate-launches-phase-1-trial-for-novel-asthma-therapy 2025-05-13T23:09:35+00:00 hourly 0.9 https://trial.medpath.com/news/stylus-medicine-emerges-with-85m-to-revolutionize-in-vivo-genetic-medicines 2025-05-13T22:39:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stylus-medicine-emerges-with-85m-to-revolutionize-in-vivo-genetic-medicines 2025-05-13T22:39:37+00:00 hourly 0.9 https://trial.medpath.com/news/artiva-s-allonk-cell-therapy-shows-durable-response-in-lymphoma-patients-in-phase-1-2-trial 2025-05-13T22:12:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/artiva-s-allonk-cell-therapy-shows-durable-response-in-lymphoma-patients-in-phase-1-2-trial 2025-05-13T22:12:26+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-study-confirms-bevacizumab-benefits-limited-to-high-risk-epithelial-ovarian-cancer-patients 2025-05-13T22:12:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-study-confirms-bevacizumab-benefits-limited-to-high-risk-epithelial-ovarian-cancer-patients 2025-05-13T22:12:21+00:00 hourly 0.9 https://trial.medpath.com/news/valinor-discovery-emerges-from-stealth-with-ai-platform-to-simulate-drug-efficacy-before-clinical-trials 2025-05-13T21:43:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/valinor-discovery-emerges-from-stealth-with-ai-platform-to-simulate-drug-efficacy-before-clinical-trials 2025-05-13T21:43:59+00:00 hourly 0.9 https://trial.medpath.com/news/gensco-pharma-acquires-global-rights-to-rizafilm-and-rizaport-for-migraine-treatment 2025-05-13T21:42:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gensco-pharma-acquires-global-rights-to-rizafilm-and-rizaport-for-migraine-treatment 2025-05-13T21:42:11+00:00 hourly 0.9 https://trial.medpath.com/news/pluto-bio-secures-3-6m-to-expand-ai-powered-platform-for-drug-discovery 2025-05-13T21:42:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pluto-bio-secures-3-6m-to-expand-ai-powered-platform-for-drug-discovery 2025-05-13T21:42:07+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-s-azd1390-enters-gbm-agile-trial-for-newly-diagnosed-glioblastoma-patients 2025-05-13T20:40:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-s-azd1390-enters-gbm-agile-trial-for-newly-diagnosed-glioblastoma-patients 2025-05-13T20:40:08+00:00 hourly 0.9 https://trial.medpath.com/news/new-ultrasound-bioprinter-enables-non-invasive-3d-printing-inside-the-body 2025-05-13T20:39:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-ultrasound-bioprinter-enables-non-invasive-3d-printing-inside-the-body 2025-05-13T20:39:33+00:00 hourly 0.9 https://trial.medpath.com/news/anito-cel-shows-promise-as-novel-bcma-targeted-car-t-therapy-for-multiple-myeloma 2025-05-13T20:38:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/anito-cel-shows-promise-as-novel-bcma-targeted-car-t-therapy-for-multiple-myeloma 2025-05-13T20:38:56+00:00 hourly 0.9 https://trial.medpath.com/news/sonoma-biotherapeutics-strengthens-leadership-team-with-appointment-of-rajesh-krishnan-as-chief-technical-officer 2025-05-13T20:37:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sonoma-biotherapeutics-strengthens-leadership-team-with-appointment-of-rajesh-krishnan-as-chief-technical-officer 2025-05-13T20:37:43+00:00 hourly 0.9 https://trial.medpath.com/news/bionxt-centralizes-r-d-operations-in-munich-to-accelerate-ms-drug-development 2025-05-13T20:37:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bionxt-centralizes-r-d-operations-in-munich-to-accelerate-ms-drug-development 2025-05-13T20:37:40+00:00 hourly 0.9 https://trial.medpath.com/news/absci-doses-first-participants-in-phase-1-trial-of-ai-designed-anti-tl1a-antibody-for-ibd 2025-05-13T20:37:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/absci-doses-first-participants-in-phase-1-trial-of-ai-designed-anti-tl1a-antibody-for-ibd 2025-05-13T20:37:28+00:00 hourly 0.9 https://trial.medpath.com/news/caretech-human-secures-500000-to-advance-ai-powered-urological-monitoring-device-in-clinical-trials 2025-05-13T20:36:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/caretech-human-secures-500000-to-advance-ai-powered-urological-monitoring-device-in-clinical-trials 2025-05-13T20:36:21+00:00 hourly 0.9 https://trial.medpath.com/news/maryland-stem-cell-research-fund-allocates-18-million-to-advance-regenerative-medicine-research 2025-05-13T20:36:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/maryland-stem-cell-research-fund-allocates-18-million-to-advance-regenerative-medicine-research 2025-05-13T20:36:20+00:00 hourly 0.9 https://trial.medpath.com/news/somite-ai-secures-47m-series-a-to-transform-cell-therapy-with-foundation-models 2025-05-13T20:36:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/somite-ai-secures-47m-series-a-to-transform-cell-therapy-with-foundation-models 2025-05-13T20:36:03+00:00 hourly 0.9 https://trial.medpath.com/news/china-approves-remegen-s-disitamab-vedotin-for-her2-positive-advanced-breast-cancer-with-liver-metastasis 2025-05-13T20:16:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-approves-remegen-s-disitamab-vedotin-for-her2-positive-advanced-breast-cancer-with-liver-metastasis 2025-05-13T20:16:29+00:00 hourly 0.9 https://trial.medpath.com/news/apreo-health-unveils-novel-airway-scaffold-for-severe-emphysema-treatment-at-ats-2025 2025-05-13T20:16:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/apreo-health-unveils-novel-airway-scaffold-for-severe-emphysema-treatment-at-ats-2025 2025-05-13T20:16:07+00:00 hourly 0.9 https://trial.medpath.com/news/know-biological-s-voli-seizure-monitor-receives-fda-breakthrough-device-designation 2025-05-13T20:16:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/know-biological-s-voli-seizure-monitor-receives-fda-breakthrough-device-designation 2025-05-13T20:16:06+00:00 hourly 0.9 https://trial.medpath.com/news/mount-sinai-s-personalized-vaccine-shows-promise-in-bladder-cancer-clinical-trial 2025-05-13T20:16:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mount-sinai-s-personalized-vaccine-shows-promise-in-bladder-cancer-clinical-trial 2025-05-13T20:16:04+00:00 hourly 0.9 https://trial.medpath.com/news/three-year-robust-iii-data-confirms-optilume-drug-coated-balloon-s-durability-for-urethral-strictures 2025-05-13T20:16:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/three-year-robust-iii-data-confirms-optilume-drug-coated-balloon-s-durability-for-urethral-strictures 2025-05-13T20:16:03+00:00 hourly 0.9 https://trial.medpath.com/news/ao-foundation-partners-with-trial-interactive-to-modernize-clinical-trial-management-for-musculoskeletal-research 2025-05-13T20:14:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ao-foundation-partners-with-trial-interactive-to-modernize-clinical-trial-management-for-musculoskeletal-research 2025-05-13T20:14:21+00:00 hourly 0.9 https://trial.medpath.com/news/recipharm-and-plg-form-strategic-alliance-to-streamline-drug-development-and-regulatory-approval 2025-05-13T20:13:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/recipharm-and-plg-form-strategic-alliance-to-streamline-drug-development-and-regulatory-approval 2025-05-13T20:13:09+00:00 hourly 0.9 https://trial.medpath.com/news/polynovo-s-novosorb-shows-promising-results-in-type-1-diabetes-wound-treatment-study 2025-05-13T18:41:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/polynovo-s-novosorb-shows-promising-results-in-type-1-diabetes-wound-treatment-study 2025-05-13T18:41:54+00:00 hourly 0.9 https://trial.medpath.com/news/phase-3b-trial-shows-colonoscopic-administration-of-rebyota-effective-for-preventing-recurrent-c-difficile-infection 2025-05-13T18:11:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-3b-trial-shows-colonoscopic-administration-of-rebyota-effective-for-preventing-recurrent-c-difficile-infection 2025-05-13T18:11:06+00:00 hourly 0.9 https://trial.medpath.com/news/affinia-therapeutics-advances-novel-gene-therapy-for-bag3-dilated-cardiomyopathy-with-promising-preclinical-results 2025-05-13T18:10:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/affinia-therapeutics-advances-novel-gene-therapy-for-bag3-dilated-cardiomyopathy-with-promising-preclinical-results 2025-05-13T18:10:08+00:00 hourly 0.9 https://trial.medpath.com/news/weight-loss-injections-show-promise-for-obese-children-reducing-mealtime-conflicts 2025-05-13T17:39:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/weight-loss-injections-show-promise-for-obese-children-reducing-mealtime-conflicts 2025-05-13T17:39:44+00:00 hourly 0.9 https://trial.medpath.com/news/exmoor-pharma-and-ku-leuven-form-strategic-alliance-to-accelerate-aav-gene-therapy-development 2025-05-13T17:10:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/exmoor-pharma-and-ku-leuven-form-strategic-alliance-to-accelerate-aav-gene-therapy-development 2025-05-13T17:10:51+00:00 hourly 0.9 https://trial.medpath.com/news/nrx-pharmaceuticals-acquires-kadima-neuropsychiatry-institute-to-launch-100m-mental-health-clinic-network 2025-05-13T16:45:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nrx-pharmaceuticals-acquires-kadima-neuropsychiatry-institute-to-launch-100m-mental-health-clinic-network 2025-05-13T16:45:54+00:00 hourly 0.9 https://trial.medpath.com/news/algernon-pharmaceuticals-enters-alzheimer-s-diagnostic-market-with-nobrainer-imaging-centers-acquisition 2025-05-13T16:44:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/algernon-pharmaceuticals-enters-alzheimer-s-diagnostic-market-with-nobrainer-imaging-centers-acquisition 2025-05-13T16:44:24+00:00 hourly 0.9 https://trial.medpath.com/news/compugen-announces-key-leadership-transition-ceo-cohen-dayag-to-become-executive-chair-as-cso-ophir-takes-helm 2025-05-13T16:44:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/compugen-announces-key-leadership-transition-ceo-cohen-dayag-to-become-executive-chair-as-cso-ophir-takes-helm 2025-05-13T16:44:16+00:00 hourly 0.9 https://trial.medpath.com/news/upc-dismisses-sanofi-s-infringement-claim-against-amgen-s-repatha-in-landmark-pcsk9-inhibitor-ruling 2025-05-13T16:43:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/upc-dismisses-sanofi-s-infringement-claim-against-amgen-s-repatha-in-landmark-pcsk9-inhibitor-ruling 2025-05-13T16:43:54+00:00 hourly 0.9 https://trial.medpath.com/news/hcw-biologics-novel-fusion-protein-shows-promise-for-revolutionizing-car-t-cell-production 2025-05-13T16:29:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hcw-biologics-novel-fusion-protein-shows-promise-for-revolutionizing-car-t-cell-production 2025-05-13T16:29:08+00:00 hourly 0.9 https://trial.medpath.com/news/ellipsoid-zone-integrity-linked-to-visual-function-in-geographic-atrophy-patients 2025-05-13T16:28:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ellipsoid-zone-integrity-linked-to-visual-function-in-geographic-atrophy-patients 2025-05-13T16:28:34+00:00 hourly 0.9 https://trial.medpath.com/news/tilt-biotherapeutics-secures-25-6m-series-b-to-advance-novel-oncolytic-virus-therapy-for-ovarian-cancer 2025-05-13T16:28:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tilt-biotherapeutics-secures-25-6m-series-b-to-advance-novel-oncolytic-virus-therapy-for-ovarian-cancer 2025-05-13T16:28:30+00:00 hourly 0.9 https://trial.medpath.com/news/landmark-science-launches-specialized-rwe-solutions-to-bridge-biopharma-vendor-gap 2025-05-13T16:28:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/landmark-science-launches-specialized-rwe-solutions-to-bridge-biopharma-vendor-gap 2025-05-13T16:28:21+00:00 hourly 0.9 https://trial.medpath.com/news/hyundai-adm-bio-pivots-strategy-to-focus-on-immunotherapy-combinations-for-cancer-treatment 2025-05-13T16:27:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hyundai-adm-bio-pivots-strategy-to-focus-on-immunotherapy-combinations-for-cancer-treatment 2025-05-13T16:27:44+00:00 hourly 0.9 https://trial.medpath.com/news/sanyou-bio-and-transrecobio-form-strategic-alliance-to-accelerate-novel-drug-development-in-china 2025-05-13T16:26:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanyou-bio-and-transrecobio-form-strategic-alliance-to-accelerate-novel-drug-development-in-china 2025-05-13T16:26:40+00:00 hourly 0.9 https://trial.medpath.com/news/takeda-s-adzynma-becomes-first-uk-approved-treatment-for-rare-blood-clotting-disorder-cttp 2025-05-13T16:18:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/takeda-s-adzynma-becomes-first-uk-approved-treatment-for-rare-blood-clotting-disorder-cttp 2025-05-13T16:18:30+00:00 hourly 0.9 https://trial.medpath.com/news/bevacizumab-capecitabine-combination-shows-promise-for-elderly-patients-with-metastatic-colorectal-cancer 2025-05-13T16:18:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bevacizumab-capecitabine-combination-shows-promise-for-elderly-patients-with-metastatic-colorectal-cancer 2025-05-13T16:18:25+00:00 hourly 0.9 https://trial.medpath.com/news/myrtelle-to-share-first-year-insights-from-fda-s-start-pilot-program-for-rare-disease-therapies-at-asgct-2025 2025-05-13T16:18:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/myrtelle-to-share-first-year-insights-from-fda-s-start-pilot-program-for-rare-disease-therapies-at-asgct-2025 2025-05-13T16:18:24+00:00 hourly 0.9 https://trial.medpath.com/news/mindera-health-s-mind-px-test-demonstrates-improved-outcomes-in-randomized-psoriasis-trial 2025-05-13T16:18:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mindera-health-s-mind-px-test-demonstrates-improved-outcomes-in-randomized-psoriasis-trial 2025-05-13T16:18:16+00:00 hourly 0.9 https://trial.medpath.com/news/prevencio-s-ai-powered-blood-test-for-coronary-artery-disease-receives-fda-breakthrough-device-designation 2025-05-13T16:17:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prevencio-s-ai-powered-blood-test-for-coronary-artery-disease-receives-fda-breakthrough-device-designation 2025-05-13T16:17:36+00:00 hourly 0.9 https://trial.medpath.com/news/eligo-bioscience-secures-5m-grant-to-advance-microbiome-based-gene-therapy-for-skin-diseases 2025-05-13T16:17:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eligo-bioscience-secures-5m-grant-to-advance-microbiome-based-gene-therapy-for-skin-diseases 2025-05-13T16:17:34+00:00 hourly 0.9 https://trial.medpath.com/news/eur26-2-million-greg-initiative-launches-to-transform-real-world-evidence-practices-across-europe 2025-05-13T16:16:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eur26-2-million-greg-initiative-launches-to-transform-real-world-evidence-practices-across-europe 2025-05-13T16:16:11+00:00 hourly 0.9 https://trial.medpath.com/news/prorx-pharma-and-gatlan-form-strategic-partnership-to-advance-men-s-health-products 2025-05-13T16:16:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prorx-pharma-and-gatlan-form-strategic-partnership-to-advance-men-s-health-products 2025-05-13T16:16:09+00:00 hourly 0.9 https://trial.medpath.com/news/fda-expands-optison-ultrasound-enhancing-agent-approval-for-pediatric-cardiac-imaging 2025-05-13T16:16:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-expands-optison-ultrasound-enhancing-agent-approval-for-pediatric-cardiac-imaging 2025-05-13T16:16:07+00:00 hourly 0.9 https://trial.medpath.com/news/olaparib-before-surgery-shows-100-survival-rate-in-brca-mutated-breast-cancer-patients 2025-05-13T16:15:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/olaparib-before-surgery-shows-100-survival-rate-in-brca-mutated-breast-cancer-patients 2025-05-13T16:15:56+00:00 hourly 0.9 https://trial.medpath.com/news/phasev-secures-50m-series-a-to-transform-clinical-trials-with-ai-platform 2025-05-13T16:15:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phasev-secures-50m-series-a-to-transform-clinical-trials-with-ai-platform 2025-05-13T16:15:52+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-and-iteos-terminate-tigit-cancer-drug-development-after-phase-2-failure 2025-05-13T16:11:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-and-iteos-terminate-tigit-cancer-drug-development-after-phase-2-failure 2025-05-13T16:11:33+00:00 hourly 0.9 https://trial.medpath.com/news/atossa-therapeutics-shifts-focus-to-metastatic-breast-cancer-with-z-endoxifen-strengthens-patent-portfolio 2025-05-13T15:10:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/atossa-therapeutics-shifts-focus-to-metastatic-breast-cancer-with-z-endoxifen-strengthens-patent-portfolio 2025-05-13T15:10:41+00:00 hourly 0.9 https://trial.medpath.com/news/indivior-advances-gabab-positive-allosteric-modulator-through-ind-enabling-studies-for-substance-use-disorders 2025-05-13T15:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/indivior-advances-gabab-positive-allosteric-modulator-through-ind-enabling-studies-for-substance-use-disorders 2025-05-13T15:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-nanotechnology-targeted-liposomes-dramatically-enhance-antifungal-treatment-against-resistant-candida 2025-05-13T13:42:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-nanotechnology-targeted-liposomes-dramatically-enhance-antifungal-treatment-against-resistant-candida 2025-05-13T13:42:28+00:00 hourly 0.9 https://trial.medpath.com/news/axsome-therapeutics-secures-570-million-credit-facility-from-blackstone-to-strengthen-cns-portfolio 2025-05-13T13:06:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/axsome-therapeutics-secures-570-million-credit-facility-from-blackstone-to-strengthen-cns-portfolio 2025-05-13T13:06:04+00:00 hourly 0.9 https://trial.medpath.com/news/cns-pharmaceuticals-secures-orphan-drug-designation-for-tpi-287-in-brain-cancer-treatment 2025-05-13T12:37:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cns-pharmaceuticals-secures-orphan-drug-designation-for-tpi-287-in-brain-cancer-treatment 2025-05-13T12:37:37+00:00 hourly 0.9 https://trial.medpath.com/news/ten-year-aphinity-data-shows-perjeta-based-regimen-reduces-death-risk-by-17-in-her2-positive-early-breast-cancer 2025-05-13T12:36:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ten-year-aphinity-data-shows-perjeta-based-regimen-reduces-death-risk-by-17-in-her2-positive-early-breast-cancer 2025-05-13T12:36:11+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-to-present-groundbreaking-respiratory-research-at-ats-2025-conference 2025-05-13T12:36:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-to-present-groundbreaking-respiratory-research-at-ats-2025-conference 2025-05-13T12:36:09+00:00 hourly 0.9 https://trial.medpath.com/news/ema-approves-moleculin-s-phase-iib-iii-trial-application-for-aml-treatment 2025-05-13T12:35:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-approves-moleculin-s-phase-iib-iii-trial-application-for-aml-treatment 2025-05-13T12:35:05+00:00 hourly 0.9 https://trial.medpath.com/news/emcutix-and-mantra-pharma-launch-advanced-urea-based-moisturizer-for-hyperkeratotic-skin-conditions 2025-05-13T12:34:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/emcutix-and-mantra-pharma-launch-advanced-urea-based-moisturizer-for-hyperkeratotic-skin-conditions 2025-05-13T12:34:32+00:00 hourly 0.9 https://trial.medpath.com/news/global-thrombocytopenia-clinical-trials-market-sees-significant-growth-in-2025 2025-05-13T12:05:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-thrombocytopenia-clinical-trials-market-sees-significant-growth-in-2025 2025-05-13T12:05:29+00:00 hourly 0.9 https://trial.medpath.com/news/expres2ion-amends-clinical-trial-protocol-to-test-breast-cancer-vaccine-in-combination-with-antibody-drug-conjugates 2025-05-13T12:05:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/expres2ion-amends-clinical-trial-protocol-to-test-breast-cancer-vaccine-in-combination-with-antibody-drug-conjugates 2025-05-13T12:05:24+00:00 hourly 0.9 https://trial.medpath.com/news/long-term-real-world-data-confirms-pitolisant-safety-and-efficacy-in-narcolepsy-patients 2025-05-13T12:05:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/long-term-real-world-data-confirms-pitolisant-safety-and-efficacy-in-narcolepsy-patients 2025-05-13T12:05:15+00:00 hourly 0.9 https://trial.medpath.com/news/iotamotion-expands-robotic-cochlear-implant-technology-internationally-with-swiss-clinical-trial 2025-05-13T11:51:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iotamotion-expands-robotic-cochlear-implant-technology-internationally-with-swiss-clinical-trial 2025-05-13T11:51:00+00:00 hourly 0.9 https://trial.medpath.com/news/roche-invests-in-new-manufacturing-facility-in-north-carolina-to-expand-biopharmaceutical-production 2025-05-13T10:10:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-invests-in-new-manufacturing-facility-in-north-carolina-to-expand-biopharmaceutical-production 2025-05-13T10:10:59+00:00 hourly 0.9 https://trial.medpath.com/news/cepi-invests-2-87-million-in-acm-biolabs-thermostable-mrna-vaccine-delivery-platform 2025-05-13T08:37:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cepi-invests-2-87-million-in-acm-biolabs-thermostable-mrna-vaccine-delivery-platform 2025-05-13T08:37:14+00:00 hourly 0.9 https://trial.medpath.com/news/irlab-secures-extended-patent-protection-for-parkinson-s-drug-candidate-mesdopetam 2025-05-13T08:36:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/irlab-secures-extended-patent-protection-for-parkinson-s-drug-candidate-mesdopetam 2025-05-13T08:36:43+00:00 hourly 0.9 https://trial.medpath.com/news/cereno-scientific-reports-promising-phase-iia-results-for-cs1-in-pulmonary-arterial-hypertension 2025-05-13T08:36:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cereno-scientific-reports-promising-phase-iia-results-for-cs1-in-pulmonary-arterial-hypertension 2025-05-13T08:36:02+00:00 hourly 0.9 https://trial.medpath.com/news/eg-427-showcases-breakthrough-dual-transgene-hsv-1-vector-technology-at-asgct-meeting 2025-05-13T08:35:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eg-427-showcases-breakthrough-dual-transgene-hsv-1-vector-technology-at-asgct-meeting 2025-05-13T08:35:31+00:00 hourly 0.9 https://trial.medpath.com/news/azafaros-secures-eur130m-funding-to-advance-nizubaglustat-into-phase-iii-for-rare-lysosomal-storage-disorders 2025-05-13T08:35:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/azafaros-secures-eur130m-funding-to-advance-nizubaglustat-into-phase-iii-for-rare-lysosomal-storage-disorders 2025-05-13T08:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/azafaros-secures-eur132m-series-b-financing-to-advance-rare-lysosomal-storage-disorder-treatments 2025-05-13T08:34:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/azafaros-secures-eur132m-series-b-financing-to-advance-rare-lysosomal-storage-disorder-treatments 2025-05-13T08:34:58+00:00 hourly 0.9 https://trial.medpath.com/news/immunitybio-settles-10-5m-lawsuit-over-fda-rejection-of-cancer-drug-anktiva 2025-05-13T08:34:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunitybio-settles-10-5m-lawsuit-over-fda-rejection-of-cancer-drug-anktiva 2025-05-13T08:34:57+00:00 hourly 0.9 https://trial.medpath.com/news/innogen-seeks-100-million-hong-kong-ipo-to-advance-glp-1-pipeline 2025-05-13T08:34:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/innogen-seeks-100-million-hong-kong-ipo-to-advance-glp-1-pipeline 2025-05-13T08:34:53+00:00 hourly 0.9 https://trial.medpath.com/news/abbisko-s-irpagratinib-atezolizumab-combination-shows-promising-results-for-advanced-liver-cancer 2025-05-13T08:34:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbisko-s-irpagratinib-atezolizumab-combination-shows-promising-results-for-advanced-liver-cancer 2025-05-13T08:34:48+00:00 hourly 0.9 https://trial.medpath.com/news/biovica-partners-with-tempus-to-expand-access-to-divitum-tka-blood-test-for-metastatic-breast-cancer-monitoring 2025-05-13T08:34:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biovica-partners-with-tempus-to-expand-access-to-divitum-tka-blood-test-for-metastatic-breast-cancer-monitoring 2025-05-13T08:34:44+00:00 hourly 0.9 https://trial.medpath.com/news/seastar-medical-reaches-halfway-enrollment-milestone-in-pivotal-neutralize-aki-trial-for-acute-kidney-injury 2025-05-13T08:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/seastar-medical-reaches-halfway-enrollment-milestone-in-pivotal-neutralize-aki-trial-for-acute-kidney-injury 2025-05-13T08:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-sydney-secures-8-3-million-for-innovative-clinical-trials-in-cancer-and-addiction-treatment 2025-05-13T08:04:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/university-of-sydney-secures-8-3-million-for-innovative-clinical-trials-in-cancer-and-addiction-treatment 2025-05-13T08:04:48+00:00 hourly 0.9 https://trial.medpath.com/news/herantis-pharma-advances-her-096-for-parkinson-s-disease-final-cohort-of-phase-1b-trial-now-underway 2025-05-13T08:04:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/herantis-pharma-advances-her-096-for-parkinson-s-disease-final-cohort-of-phase-1b-trial-now-underway 2025-05-13T08:04:46+00:00 hourly 0.9 https://trial.medpath.com/news/abl-bio-secures-major-platform-deal-with-gsk-eyes-future-acquisition 2025-05-13T08:04:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abl-bio-secures-major-platform-deal-with-gsk-eyes-future-acquisition 2025-05-13T08:04:45+00:00 hourly 0.9 https://trial.medpath.com/news/first-oral-treatment-for-deadly-rhodesiense-sleeping-sickness-now-available-in-three-african-countries 2025-05-13T07:34:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-oral-treatment-for-deadly-rhodesiense-sleeping-sickness-now-available-in-three-african-countries 2025-05-13T07:34:11+00:00 hourly 0.9 https://trial.medpath.com/news/axovia-therapeutics-advances-gene-therapy-for-bardet-biedl-syndrome-blindness-with-promising-preclinical-data 2025-05-13T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/axovia-therapeutics-advances-gene-therapy-for-bardet-biedl-syndrome-blindness-with-promising-preclinical-data 2025-05-13T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/royalty-pharma-secures-99-9-shareholder-approval-for-1-1-billion-external-manager-acquisition 2025-05-13T06:39:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/royalty-pharma-secures-99-9-shareholder-approval-for-1-1-billion-external-manager-acquisition 2025-05-13T06:39:30+00:00 hourly 0.9 https://trial.medpath.com/news/ring-therapeutics-unveils-breakthrough-anellobricks-platform-for-low-cost-gene-therapy-manufacturing 2025-05-13T06:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ring-therapeutics-unveils-breakthrough-anellobricks-platform-for-low-cost-gene-therapy-manufacturing 2025-05-13T06:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/qiagen-acquires-genoox-for-70-million-to-strengthen-ai-powered-genomic-analysis-capabilities 2025-05-13T05:06:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/qiagen-acquires-genoox-for-70-million-to-strengthen-ai-powered-genomic-analysis-capabilities 2025-05-13T05:06:07+00:00 hourly 0.9 https://trial.medpath.com/news/engeneic-launches-phase-i-iia-trial-of-novel-edv-nanocell-therapy-for-egfr-positive-advanced-cancers 2025-05-13T04:46:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/engeneic-launches-phase-i-iia-trial-of-novel-edv-nanocell-therapy-for-egfr-positive-advanced-cancers 2025-05-13T04:46:05+00:00 hourly 0.9 https://trial.medpath.com/news/innovo-s-novel-immuno-metabolic-drug-shows-promising-safety-profile-in-phase-1-trial 2025-05-13T04:45:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/innovo-s-novel-immuno-metabolic-drug-shows-promising-safety-profile-in-phase-1-trial 2025-05-13T04:45:36+00:00 hourly 0.9 https://trial.medpath.com/news/injectable-drug-delivery-market-projected-to-reach-1-14-trillion-by-2029-as-industry-leaders-convene-for-innovation-summit 2025-05-13T03:17:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/injectable-drug-delivery-market-projected-to-reach-1-14-trillion-by-2029-as-industry-leaders-convene-for-innovation-summit 2025-05-13T03:17:11+00:00 hourly 0.9 https://trial.medpath.com/news/federal-appeals-court-reopens-crispr-patent-battle-giving-nobel-laureates-new-hope 2025-05-13T03:13:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-appeals-court-reopens-crispr-patent-battle-giving-nobel-laureates-new-hope 2025-05-13T03:13:04+00:00 hourly 0.9 https://trial.medpath.com/news/mayo-clinic-expert-highlights-advancements-and-challenges-in-minimal-residual-disease-detection 2025-05-13T03:11:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mayo-clinic-expert-highlights-advancements-and-challenges-in-minimal-residual-disease-detection 2025-05-13T03:11:10+00:00 hourly 0.9 https://trial.medpath.com/news/experts-emphasize-need-for-patient-centered-value-in-healthcare-research 2025-05-13T03:11:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/experts-emphasize-need-for-patient-centered-value-in-healthcare-research 2025-05-13T03:11:06+00:00 hourly 0.9 https://trial.medpath.com/news/nsd2-overexpression-in-multiple-myeloma-may-drive-immune-evasion-new-research-suggests 2025-05-13T02:41:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nsd2-overexpression-in-multiple-myeloma-may-drive-immune-evasion-new-research-suggests 2025-05-13T02:41:55+00:00 hourly 0.9 https://trial.medpath.com/news/navigating-advanced-endometrial-cancer-treatment-expert-guidance-for-community-oncologists 2025-05-13T02:40:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/navigating-advanced-endometrial-cancer-treatment-expert-guidance-for-community-oncologists 2025-05-13T02:40:54+00:00 hourly 0.9 https://trial.medpath.com/news/transcon-pth-shows-sustained-4-year-efficacy-in-hypoparathyroidism-patients 2025-05-13T02:14:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/transcon-pth-shows-sustained-4-year-efficacy-in-hypoparathyroidism-patients 2025-05-13T02:14:11+00:00 hourly 0.9 https://trial.medpath.com/news/car-t-cell-therapy-emerges-as-promising-strategy-for-glioblastoma-treatment 2025-05-13T02:12:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/car-t-cell-therapy-emerges-as-promising-strategy-for-glioblastoma-treatment 2025-05-13T02:12:35+00:00 hourly 0.9 https://trial.medpath.com/news/stanford-study-reveals-car-t-cell-therapy-may-cause-mild-cognitive-impairment-in-cancer-patients 2025-05-13T01:40:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stanford-study-reveals-car-t-cell-therapy-may-cause-mild-cognitive-impairment-in-cancer-patients 2025-05-13T01:40:29+00:00 hourly 0.9 https://trial.medpath.com/news/federal-circuit-remands-crispr-patent-dispute-to-ptab-in-ongoing-editas-medicine-case 2025-05-13T01:10:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-circuit-remands-crispr-patent-dispute-to-ptab-in-ongoing-editas-medicine-case 2025-05-13T01:10:52+00:00 hourly 0.9 https://trial.medpath.com/news/nmd-pharma-presents-preclinical-data-on-clc-1-ion-channel-inhibition-for-musk-myasthenia-gravis-treatment 2025-05-13T01:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nmd-pharma-presents-preclinical-data-on-clc-1-ion-channel-inhibition-for-musk-myasthenia-gravis-treatment 2025-05-13T01:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/syndax-pharmaceuticals-appoints-dr-nicholas-botwood-as-new-r-d-head-and-chief-medical-officer 2025-05-13T00:36:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/syndax-pharmaceuticals-appoints-dr-nicholas-botwood-as-new-r-d-head-and-chief-medical-officer 2025-05-13T00:36:23+00:00 hourly 0.9 https://trial.medpath.com/news/nih-grants-exclusive-license-to-sangam-lifesciences-for-novel-cancer-drug-delivery-platform 2025-05-13T00:35:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nih-grants-exclusive-license-to-sangam-lifesciences-for-novel-cancer-drug-delivery-platform 2025-05-13T00:35:43+00:00 hourly 0.9 https://trial.medpath.com/news/1-25-million-boost-for-novel-prostate-cancer-drug-qed-203-targeting-advanced-disease 2025-05-13T00:35:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/1-25-million-boost-for-novel-prostate-cancer-drug-qed-203-targeting-advanced-disease 2025-05-13T00:35:36+00:00 hourly 0.9 https://trial.medpath.com/news/uk-researchers-begin-clinical-trials-for-novel-african-swine-fever-vaccine 2025-05-13T00:10:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-researchers-begin-clinical-trials-for-novel-african-swine-fever-vaccine 2025-05-13T00:10:53+00:00 hourly 0.9 https://trial.medpath.com/news/invivyd-initiates-measles-monoclonal-antibody-discovery-program-to-address-critical-treatment-gap 2025-05-13T00:10:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/invivyd-initiates-measles-monoclonal-antibody-discovery-program-to-address-critical-treatment-gap 2025-05-13T00:10:16+00:00 hourly 0.9 https://trial.medpath.com/news/bright-minds-bmb-101-completely-eliminates-drop-attacks-in-preclinical-sudep-model 2025-05-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bright-minds-bmb-101-completely-eliminates-drop-attacks-in-preclinical-sudep-model 2025-05-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/newcastle-university-spin-out-fibrofind-acquired-by-vespa-capital-to-accelerate-fibrosis-drug-development 2025-05-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/newcastle-university-spin-out-fibrofind-acquired-by-vespa-capital-to-accelerate-fibrosis-drug-development 2025-05-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/apyx-medical-receives-fda-clearance-for-ayon-body-contouring-system-first-all-in-one-aesthetic-platform 2025-05-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/apyx-medical-receives-fda-clearance-for-ayon-body-contouring-system-first-all-in-one-aesthetic-platform 2025-05-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-study-confirms-faricimab-s-efficacy-in-treating-diabetic-macular-edema 2025-05-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-study-confirms-faricimab-s-efficacy-in-treating-diabetic-macular-edema 2025-05-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/next-generation-vaccine-adjuvants-transform-immunotherapy-with-targeted-immune-activation 2025-05-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/next-generation-vaccine-adjuvants-transform-immunotherapy-with-targeted-immune-activation 2025-05-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-partners-with-ibm-to-advance-mrna-drug-discovery-through-quantum-computing-and-ai 2025-05-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moderna-partners-with-ibm-to-advance-mrna-drug-discovery-through-quantum-computing-and-ai 2025-05-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-tzield-as-first-disease-modifying-therapy-for-type-1-diabetes-prevention 2025-05-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-tzield-as-first-disease-modifying-therapy-for-type-1-diabetes-prevention 2025-05-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-mpox-nanoparticle-vaccine-shows-superior-protection-in-preclinical-studies 2025-05-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-mpox-nanoparticle-vaccine-shows-superior-protection-in-preclinical-studies 2025-05-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/dupilumab-shows-31-greater-likelihood-of-avoiding-negative-outcomes-in-copd-patients-with-type-2-inflammation 2025-05-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dupilumab-shows-31-greater-likelihood-of-avoiding-negative-outcomes-in-copd-patients-with-type-2-inflammation 2025-05-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/sl-bio-and-horizon-space-acquisition-ii-corp-announce-merger-to-advance-cancer-immunotherapy-and-regenerative-medicine 2025-05-12T22:41:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sl-bio-and-horizon-space-acquisition-ii-corp-announce-merger-to-advance-cancer-immunotherapy-and-regenerative-medicine 2025-05-12T22:41:03+00:00 hourly 0.9 https://trial.medpath.com/news/gop-proposes-912-billion-medicaid-cuts-despite-intra-party-opposition-and-trump-s-protection-pledge 2025-05-12T21:29:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gop-proposes-912-billion-medicaid-cuts-despite-intra-party-opposition-and-trump-s-protection-pledge 2025-05-12T21:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/medicaid-unwinding-disrupts-critical-medication-access-for-youth-with-chronic-conditions 2025-05-12T21:11:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medicaid-unwinding-disrupts-critical-medication-access-for-youth-with-chronic-conditions 2025-05-12T21:11:35+00:00 hourly 0.9 https://trial.medpath.com/news/maternal-cardiometabolic-risk-factors-during-pregnancy-linked-to-higher-blood-pressure-in-children 2025-05-12T21:11:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/maternal-cardiometabolic-risk-factors-during-pregnancy-linked-to-higher-blood-pressure-in-children 2025-05-12T21:11:32+00:00 hourly 0.9 https://trial.medpath.com/news/study-reveals-elevated-cardiovascular-risks-in-aging-down-syndrome-patients 2025-05-12T21:07:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-reveals-elevated-cardiovascular-risks-in-aging-down-syndrome-patients 2025-05-12T21:07:39+00:00 hourly 0.9 https://trial.medpath.com/news/perceived-stress-significantly-worsens-copd-outcomes-quadruples-exacerbation-risk 2025-05-12T21:06:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/perceived-stress-significantly-worsens-copd-outcomes-quadruples-exacerbation-risk 2025-05-12T21:06:53+00:00 hourly 0.9 https://trial.medpath.com/news/first-u-s-patient-successfully-treated-with-advanced-proton-arc-therapy-for-rare-cancer 2025-05-12T21:05:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-u-s-patient-successfully-treated-with-advanced-proton-arc-therapy-for-rare-cancer 2025-05-12T21:05:43+00:00 hourly 0.9 https://trial.medpath.com/news/researchers-challenge-standard-diagnostic-test-for-primary-aldosteronism-call-for-paradigm-shift-in-hypertension-care 2025-05-12T21:05:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/researchers-challenge-standard-diagnostic-test-for-primary-aldosteronism-call-for-paradigm-shift-in-hypertension-care 2025-05-12T21:05:41+00:00 hourly 0.9 https://trial.medpath.com/news/second-opinions-for-breast-cancer-patients-minimal-impact-on-treatment-timelines 2025-05-12T21:05:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/second-opinions-for-breast-cancer-patients-minimal-impact-on-treatment-timelines 2025-05-12T21:05:38+00:00 hourly 0.9 https://trial.medpath.com/news/study-reveals-1-in-10-internal-medicine-physicians-experience-high-burnout-levels 2025-05-12T21:05:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-reveals-1-in-10-internal-medicine-physicians-experience-high-burnout-levels 2025-05-12T21:05:36+00:00 hourly 0.9 https://trial.medpath.com/news/immunoprecise-s-lensai-platform-achieves-x-ray-crystallography-level-epitope-mapping-accuracy-in-hours 2025-05-12T20:46:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunoprecise-s-lensai-platform-achieves-x-ray-crystallography-level-epitope-mapping-accuracy-in-hours 2025-05-12T20:46:15+00:00 hourly 0.9 https://trial.medpath.com/news/long-term-lecanemab-treatment-shows-sustained-benefits-in-early-alzheimer-s-disease 2025-05-12T20:42:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/long-term-lecanemab-treatment-shows-sustained-benefits-in-early-alzheimer-s-disease 2025-05-12T20:42:57+00:00 hourly 0.9 https://trial.medpath.com/news/federal-circuit-revives-uc-s-crispr-patent-claims-orders-re-evaluation-of-gene-editing-breakthrough 2025-05-12T20:42:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-circuit-revives-uc-s-crispr-patent-claims-orders-re-evaluation-of-gene-editing-breakthrough 2025-05-12T20:42:47+00:00 hourly 0.9 https://trial.medpath.com/news/ut-southwestern-breaks-ground-on-177m-radiation-oncology-campus-in-fort-worth 2025-05-12T20:41:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ut-southwestern-breaks-ground-on-177m-radiation-oncology-campus-in-fort-worth 2025-05-12T20:41:35+00:00 hourly 0.9 https://trial.medpath.com/news/piramal-pharma-commits-90-million-to-expand-us-manufacturing-facilities-amid-reshoring-trend 2025-05-12T20:14:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/piramal-pharma-commits-90-million-to-expand-us-manufacturing-facilities-amid-reshoring-trend 2025-05-12T20:14:01+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-united-imaging-s-uangio-aviva-first-interventional-x-ray-system-with-voice-control 2025-05-12T20:12:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-united-imaging-s-uangio-aviva-first-interventional-x-ray-system-with-voice-control 2025-05-12T20:12:45+00:00 hourly 0.9 https://trial.medpath.com/news/pharma-vc-investments-reach-6-5-billion-in-q1-2025-with-oncology-leading-the-pack 2025-05-12T19:11:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharma-vc-investments-reach-6-5-billion-in-q1-2025-with-oncology-leading-the-pack 2025-05-12T19:11:20+00:00 hourly 0.9 https://trial.medpath.com/news/caris-life-sciences-pioneers-met-ihc-testing-for-non-squamous-nsclc-patients 2025-05-12T18:10:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/caris-life-sciences-pioneers-met-ihc-testing-for-non-squamous-nsclc-patients 2025-05-12T18:10:46+00:00 hourly 0.9 https://trial.medpath.com/news/marvel-biosciences-raises-1-02-million-to-advance-novel-neurological-drug-mb-204 2025-05-12T18:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/marvel-biosciences-raises-1-02-million-to-advance-novel-neurological-drug-mb-204 2025-05-12T18:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/regeneron-secures-fda-approval-for-bcma-targeted-bispecific-antibody-in-multiple-myeloma 2025-05-12T17:02:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regeneron-secures-fda-approval-for-bcma-targeted-bispecific-antibody-in-multiple-myeloma 2025-05-12T17:02:04+00:00 hourly 0.9 https://trial.medpath.com/news/aranscia-acquires-spesana-to-enhance-precision-medicine-workflow-solutions 2025-05-12T16:47:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aranscia-acquires-spesana-to-enhance-precision-medicine-workflow-solutions 2025-05-12T16:47:15+00:00 hourly 0.9 https://trial.medpath.com/news/secarna-pharmaceuticals-and-curie-bio-portfolio-company-form-strategic-alliance-to-develop-novel-oligonucleotide-therapeutics 2025-05-12T16:45:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/secarna-pharmaceuticals-and-curie-bio-portfolio-company-form-strategic-alliance-to-develop-novel-oligonucleotide-therapeutics 2025-05-12T16:45:23+00:00 hourly 0.9 https://trial.medpath.com/news/roche-invests-300-million-in-new-shanghai-biologics-manufacturing-facility 2025-05-12T16:45:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-invests-300-million-in-new-shanghai-biologics-manufacturing-facility 2025-05-12T16:45:21+00:00 hourly 0.9 https://trial.medpath.com/news/n4-pharma-reports-positive-results-from-first-in-vivo-study-of-nuvec-r-for-inflammatory-bowel-disease 2025-05-12T16:44:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/n4-pharma-reports-positive-results-from-first-in-vivo-study-of-nuvec-r-for-inflammatory-bowel-disease 2025-05-12T16:44:43+00:00 hourly 0.9 https://trial.medpath.com/news/esperion-secures-patent-protection-for-nexletol-until-2040-through-settlement-with-micro-labs 2025-05-12T16:44:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/esperion-secures-patent-protection-for-nexletol-until-2040-through-settlement-with-micro-labs 2025-05-12T16:44:37+00:00 hourly 0.9 https://trial.medpath.com/news/synact-pharma-secures-extended-us-patent-protection-for-resomelagon-combination-therapy-until-2042 2025-05-12T16:44:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/synact-pharma-secures-extended-us-patent-protection-for-resomelagon-combination-therapy-until-2042 2025-05-12T16:44:34+00:00 hourly 0.9 https://trial.medpath.com/news/orthotrophix-launches-phase-2b-trial-of-tpx-100-for-knee-osteoarthritis-with-disease-modifying-potential 2025-05-12T16:43:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/orthotrophix-launches-phase-2b-trial-of-tpx-100-for-knee-osteoarthritis-with-disease-modifying-potential 2025-05-12T16:43:10+00:00 hourly 0.9 https://trial.medpath.com/news/ensysce-biosciences-strengthens-regulatory-team-ahead-of-critical-phase-3-trials-and-nda-submission 2025-05-12T16:42:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ensysce-biosciences-strengthens-regulatory-team-ahead-of-critical-phase-3-trials-and-nda-submission 2025-05-12T16:42:28+00:00 hourly 0.9 https://trial.medpath.com/news/bioxytran-achieves-critical-milestone-in-prolectin-m-antiviral-development 2025-05-12T16:42:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioxytran-achieves-critical-milestone-in-prolectin-m-antiviral-development 2025-05-12T16:42:05+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-ind-for-mavrix-bio-s-gene-therapy-for-angelman-syndrome-first-in-human-trial-to-begin-in-2025 2025-05-12T16:41:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-ind-for-mavrix-bio-s-gene-therapy-for-angelman-syndrome-first-in-human-trial-to-begin-in-2025 2025-05-12T16:41:57+00:00 hourly 0.9 https://trial.medpath.com/news/quidditas-secures-eur2-62m-to-advance-revolutionary-genome-editing-technology-for-rare-disease-treatment 2025-05-12T16:41:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quidditas-secures-eur2-62m-to-advance-revolutionary-genome-editing-technology-for-rare-disease-treatment 2025-05-12T16:41:55+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-capsida-s-revolutionary-iv-gene-therapy-for-stxbp1-dee-first-to-cross-blood-brain-barrier 2025-05-12T16:41:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-capsida-s-revolutionary-iv-gene-therapy-for-stxbp1-dee-first-to-cross-blood-brain-barrier 2025-05-12T16:41:23+00:00 hourly 0.9 https://trial.medpath.com/news/omeros-restructures-80-5-million-in-debt-significantly-reducing-near-term-financial-obligations 2025-05-12T16:40:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/omeros-restructures-80-5-million-in-debt-significantly-reducing-near-term-financial-obligations 2025-05-12T16:40:53+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-ind-for-ensoma-s-first-in-class-in-vivo-gene-therapy-for-x-linked-chronic-granulomatous-disease 2025-05-12T16:40:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-ind-for-ensoma-s-first-in-class-in-vivo-gene-therapy-for-x-linked-chronic-granulomatous-disease 2025-05-12T16:40:52+00:00 hourly 0.9 https://trial.medpath.com/news/andelyn-biosciences-delivers-breakthrough-gene-therapy-for-ultra-rare-nedamss-disease-in-record-time 2025-05-12T16:40:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/andelyn-biosciences-delivers-breakthrough-gene-therapy-for-ultra-rare-nedamss-disease-in-record-time 2025-05-12T16:40:50+00:00 hourly 0.9 https://trial.medpath.com/news/car-t-cell-therapy-funding-surges-to-141-2-billion-as-industry-expands-globally 2025-05-12T16:40:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/car-t-cell-therapy-funding-surges-to-141-2-billion-as-industry-expands-globally 2025-05-12T16:40:45+00:00 hourly 0.9 https://trial.medpath.com/news/igc-pharma-s-alzheimer-s-drug-igc-ad1-passes-critical-genetic-safety-test 2025-05-12T16:40:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/igc-pharma-s-alzheimer-s-drug-igc-ad1-passes-critical-genetic-safety-test 2025-05-12T16:40:11+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-targeted-therapy-for-igg4-related-disease-amgen-s-uplizna 2025-05-12T16:17:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-targeted-therapy-for-igg4-related-disease-amgen-s-uplizna 2025-05-12T16:17:17+00:00 hourly 0.9 https://trial.medpath.com/news/curaleaf-international-secures-eu-medical-device-certification-for-pioneering-cannabis-inhalation-technology 2025-05-12T16:17:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/curaleaf-international-secures-eu-medical-device-certification-for-pioneering-cannabis-inhalation-technology 2025-05-12T16:17:07+00:00 hourly 0.9 https://trial.medpath.com/news/genentech-to-invest-700-million-in-new-north-carolina-manufacturing-facility-creating-400-high-paying-jobs 2025-05-12T16:15:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genentech-to-invest-700-million-in-new-north-carolina-manufacturing-facility-creating-400-high-paying-jobs 2025-05-12T16:15:58+00:00 hourly 0.9 https://trial.medpath.com/news/nextgen-jane-secures-2-2m-nih-grant-to-validate-non-invasive-endometriosis-diagnostic 2025-05-12T16:15:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nextgen-jane-secures-2-2m-nih-grant-to-validate-non-invasive-endometriosis-diagnostic 2025-05-12T16:15:46+00:00 hourly 0.9 https://trial.medpath.com/news/grit-biotechnology-to-present-breakthrough-immunotherapy-advances-at-asgct-2025 2025-05-12T16:15:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/grit-biotechnology-to-present-breakthrough-immunotherapy-advances-at-asgct-2025 2025-05-12T16:15:36+00:00 hourly 0.9 https://trial.medpath.com/news/true-indicating-secures-fda-clearance-for-cspn-15-steam-sterilization-monitoring-device 2025-05-12T16:15:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/true-indicating-secures-fda-clearance-for-cspn-15-steam-sterilization-monitoring-device 2025-05-12T16:15:21+00:00 hourly 0.9 https://trial.medpath.com/news/vgxi-s-successful-fda-inspection-leads-to-client-s-bla-approval-strengthening-position-in-plasmid-dna-manufacturing 2025-05-12T16:15:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vgxi-s-successful-fda-inspection-leads-to-client-s-bla-approval-strengthening-position-in-plasmid-dna-manufacturing 2025-05-12T16:15:17+00:00 hourly 0.9 https://trial.medpath.com/news/inbrain-pharma-secures-eur1-8-million-to-industrialize-anaerobic-dopamine-production-for-advanced-parkinson-s-disease 2025-05-12T16:13:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inbrain-pharma-secures-eur1-8-million-to-industrialize-anaerobic-dopamine-production-for-advanced-parkinson-s-disease 2025-05-12T16:13:54+00:00 hourly 0.9 https://trial.medpath.com/news/ubrogepant-shows-promise-in-treating-migraine-prodromal-symptoms-in-phase-iii-trial 2025-05-12T16:13:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ubrogepant-shows-promise-in-treating-migraine-prodromal-symptoms-in-phase-iii-trial 2025-05-12T16:13:41+00:00 hourly 0.9 https://trial.medpath.com/news/36-month-results-of-opregen-cell-therapy-for-geographic-atrophy-to-be-presented-at-cts-2025 2025-05-12T16:13:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/36-month-results-of-opregen-cell-therapy-for-geographic-atrophy-to-be-presented-at-cts-2025 2025-05-12T16:13:37+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approved-alzheimer-s-drug-lecanemab-shows-manageable-safety-profile-in-real-world-setting 2025-05-12T16:13:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approved-alzheimer-s-drug-lecanemab-shows-manageable-safety-profile-in-real-world-setting 2025-05-12T16:13:32+00:00 hourly 0.9 https://trial.medpath.com/news/intrepid-labs-emerges-from-stealth-with-ai-powered-platform-to-revolutionize-drug-formulation 2025-05-12T14:39:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/intrepid-labs-emerges-from-stealth-with-ai-powered-platform-to-revolutionize-drug-formulation 2025-05-12T14:39:48+00:00 hourly 0.9 https://trial.medpath.com/news/veradigm-deploys-ai-to-extract-real-world-insights-on-glp-1-medications-from-ehr-data 2025-05-12T14:08:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/veradigm-deploys-ai-to-extract-real-world-insights-on-glp-1-medications-from-ehr-data 2025-05-12T14:08:24+00:00 hourly 0.9 https://trial.medpath.com/news/aura-and-life360-form-25-million-strategic-partnership-for-family-safety-solutions 2025-05-12T14:07:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aura-and-life360-form-25-million-strategic-partnership-for-family-safety-solutions 2025-05-12T14:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-s-mrna-1273-covid-19-vaccine-shows-promise-in-phase-1-trial-advances-to-phase-3-testing 2025-05-12T12:58:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moderna-s-mrna-1273-covid-19-vaccine-shows-promise-in-phase-1-trial-advances-to-phase-3-testing 2025-05-12T12:58:00+00:00 hourly 0.9 https://trial.medpath.com/news/india-rejects-uk-s-data-exclusivity-demand-to-protect-25-billion-generic-drug-industry 2025-05-12T12:36:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/india-rejects-uk-s-data-exclusivity-demand-to-protect-25-billion-generic-drug-industry 2025-05-12T12:36:12+00:00 hourly 0.9 https://trial.medpath.com/news/chong-kun-dang-invests-w10-billion-in-abclon-to-advance-car-t-and-antibody-therapies 2025-05-12T12:35:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chong-kun-dang-invests-w10-billion-in-abclon-to-advance-car-t-and-antibody-therapies 2025-05-12T12:35:59+00:00 hourly 0.9 https://trial.medpath.com/news/cytomx-s-cx-2051-shows-promising-28-response-rate-in-advanced-colorectal-cancer-phase-1-trial 2025-05-12T12:35:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cytomx-s-cx-2051-shows-promising-28-response-rate-in-advanced-colorectal-cancer-phase-1-trial 2025-05-12T12:35:44+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-and-purdue-university-forge-250-million-partnership-to-accelerate-pharmaceutical-innovation 2025-05-12T12:34:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-and-purdue-university-forge-250-million-partnership-to-accelerate-pharmaceutical-innovation 2025-05-12T12:34:27+00:00 hourly 0.9 https://trial.medpath.com/news/new-transcatheter-tricuspid-valve-treatments-offer-hope-for-high-risk-cardiac-patients 2025-05-12T12:12:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-transcatheter-tricuspid-valve-treatments-offer-hope-for-high-risk-cardiac-patients 2025-05-12T12:12:04+00:00 hourly 0.9 https://trial.medpath.com/news/thermosome-s-the001-receives-fda-orphan-drug-designation-for-soft-tissue-sarcoma-treatment 2025-05-12T12:10:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/thermosome-s-the001-receives-fda-orphan-drug-designation-for-soft-tissue-sarcoma-treatment 2025-05-12T12:10:40+00:00 hourly 0.9 https://trial.medpath.com/news/orca-bio-appoints-co-founder-nate-fernhoff-as-ceo-ahead-of-2025-bla-submission-for-orca-t 2025-05-12T11:23:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/orca-bio-appoints-co-founder-nate-fernhoff-as-ceo-ahead-of-2025-bla-submission-for-orca-t 2025-05-12T11:23:00+00:00 hourly 0.9 https://trial.medpath.com/news/zynex-submits-fda-application-for-nico-revolutionary-laser-pulse-oximeter-addresses-racial-bias-in-patient-monitoring 2025-05-12T09:15:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zynex-submits-fda-application-for-nico-revolutionary-laser-pulse-oximeter-addresses-racial-bias-in-patient-monitoring 2025-05-12T09:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/alligator-bioscience-to-present-biomarker-data-from-promising-pancreatic-cancer-trial-at-asco-2025 2025-05-12T08:40:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alligator-bioscience-to-present-biomarker-data-from-promising-pancreatic-cancer-trial-at-asco-2025 2025-05-12T08:40:50+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-s-once-weekly-sogroya-shows-efficacy-in-children-with-growth-disorders-in-phase-3-trial 2025-05-12T08:40:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-nordisk-s-once-weekly-sogroya-shows-efficacy-in-children-with-growth-disorders-in-phase-3-trial 2025-05-12T08:40:07+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-s-trixeo-aerosphere-becomes-first-inhaled-respiratory-medicine-with-near-zero-climate-impact-propellant 2025-05-12T08:39:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-s-trixeo-aerosphere-becomes-first-inhaled-respiratory-medicine-with-near-zero-climate-impact-propellant 2025-05-12T08:39:50+00:00 hourly 0.9 https://trial.medpath.com/news/leucid-bio-doses-first-patient-in-aerial-trial-of-novel-nkg2d-car-t-therapy-for-solid-tumors 2025-05-12T08:39:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/leucid-bio-doses-first-patient-in-aerial-trial-of-novel-nkg2d-car-t-therapy-for-solid-tumors 2025-05-12T08:39:47+00:00 hourly 0.9 https://trial.medpath.com/news/valirx-expands-precision-oncology-partnership-with-dominion-biotech-through-predictrx-platform-licensing 2025-05-12T08:39:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/valirx-expands-precision-oncology-partnership-with-dominion-biotech-through-predictrx-platform-licensing 2025-05-12T08:39:40+00:00 hourly 0.9 https://trial.medpath.com/news/metis-pharmaceuticals-plans-200-million-hong-kong-ipo-to-advance-ai-driven-drug-development 2025-05-12T08:39:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/metis-pharmaceuticals-plans-200-million-hong-kong-ipo-to-advance-ai-driven-drug-development 2025-05-12T08:39:10+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-aqilion-s-ind-application-for-aq280-in-eosinophilic-esophagitis-treatment 2025-05-12T08:05:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-aqilion-s-ind-application-for-aq280-in-eosinophilic-esophagitis-treatment 2025-05-12T08:05:44+00:00 hourly 0.9 https://trial.medpath.com/news/vuno-s-ai-powered-cardiac-arrest-prediction-system-secures-ce-mdr-and-ukca-certifications 2025-05-12T08:05:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vuno-s-ai-powered-cardiac-arrest-prediction-system-secures-ce-mdr-and-ukca-certifications 2025-05-12T08:05:41+00:00 hourly 0.9 https://trial.medpath.com/news/synthego-launches-gmp-spcas9-to-streamline-crispr-therapeutic-development 2025-05-12T07:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/synthego-launches-gmp-spcas9-to-streamline-crispr-therapeutic-development 2025-05-12T07:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/agenus-reports-breakthrough-response-rates-for-bot-bal-combination-in-cold-tumors 2025-05-12T07:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/agenus-reports-breakthrough-response-rates-for-bot-bal-combination-in-cold-tumors 2025-05-12T07:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/former-j-j-executive-herwig-janssen-appointed-chairman-of-tryptamine-therapeutics-as-company-advances-psilocin-based-clinical-programs 2025-05-12T04:40:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/former-j-j-executive-herwig-janssen-appointed-chairman-of-tryptamine-therapeutics-as-company-advances-psilocin-based-clinical-programs 2025-05-12T04:40:27+00:00 hourly 0.9 https://trial.medpath.com/news/radiopharm-theranostics-advances-phase-1-trial-of-pd-l1-targeting-radiotherapeutic-for-advanced-cancers 2025-05-12T04:39:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/radiopharm-theranostics-advances-phase-1-trial-of-pd-l1-targeting-radiotherapeutic-for-advanced-cancers 2025-05-12T04:39:42+00:00 hourly 0.9 https://trial.medpath.com/news/carsgen-s-allogeneic-bcma-car-t-shows-promising-safety-and-efficacy-in-relapsed-refractory-multiple-myeloma 2025-05-12T04:38:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/carsgen-s-allogeneic-bcma-car-t-shows-promising-safety-and-efficacy-in-relapsed-refractory-multiple-myeloma 2025-05-12T04:38:59+00:00 hourly 0.9 https://trial.medpath.com/news/innocare-s-mesutoclax-receives-breakthrough-therapy-designation-in-china-for-lymphoma-treatment 2025-05-12T04:08:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/innocare-s-mesutoclax-receives-breakthrough-therapy-designation-in-china-for-lymphoma-treatment 2025-05-12T04:08:23+00:00 hourly 0.9 https://trial.medpath.com/news/nanoscope-therapeutics-showcases-mco-010-optogenetic-therapy-data-at-asgct-2025 2025-05-12T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nanoscope-therapeutics-showcases-mco-010-optogenetic-therapy-data-at-asgct-2025 2025-05-12T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/weight-loss-injections-show-promising-anti-cancer-effects-beyond-weight-reduction 2025-05-12T02:04:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/weight-loss-injections-show-promising-anti-cancer-effects-beyond-weight-reduction 2025-05-12T02:04:35+00:00 hourly 0.9 https://trial.medpath.com/news/denosumab-shows-immunomodulatory-effects-in-her2-negative-early-breast-cancer 2025-05-12T00:34:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/denosumab-shows-immunomodulatory-effects-in-her2-negative-early-breast-cancer 2025-05-12T00:34:28+00:00 hourly 0.9 https://trial.medpath.com/news/wehi-3773-small-molecule-shows-promise-for-blocking-cell-death-in-neurodegenerative-diseases 2025-05-12T00:34:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wehi-3773-small-molecule-shows-promise-for-blocking-cell-death-in-neurodegenerative-diseases 2025-05-12T00:34:20+00:00 hourly 0.9 https://trial.medpath.com/news/united-healthcare-approves-reimbursement-for-helius-medical-s-pons-device-for-ms-patients 2025-05-12T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/united-healthcare-approves-reimbursement-for-helius-medical-s-pons-device-for-ms-patients 2025-05-12T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/tobin-scientific-secures-65m-investment-to-expand-life-sciences-infrastructure-and-services 2025-05-11T20:39:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tobin-scientific-secures-65m-investment-to-expand-life-sciences-infrastructure-and-services 2025-05-11T20:39:55+00:00 hourly 0.9 https://trial.medpath.com/news/saudi-arabia-seeks-to-localize-insulin-and-glp-1-production-through-novo-nordisk-partnership 2025-05-11T20:39:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/saudi-arabia-seeks-to-localize-insulin-and-glp-1-production-through-novo-nordisk-partnership 2025-05-11T20:39:43+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-acquires-esobiotec-for-1-billion-revolutionary-in-vivo-car-t-technology-to-transform-cancer-treatment 2025-05-11T20:39:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-acquires-esobiotec-for-1-billion-revolutionary-in-vivo-car-t-technology-to-transform-cancer-treatment 2025-05-11T20:39:25+00:00 hourly 0.9 https://trial.medpath.com/news/type-2-diabetes-significantly-increases-risk-of-mash-progression-to-cirrhosis-new-target-rwe-study-reveals 2025-05-11T17:36:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/type-2-diabetes-significantly-increases-risk-of-mash-progression-to-cirrhosis-new-target-rwe-study-reveals 2025-05-11T17:36:25+00:00 hourly 0.9 https://trial.medpath.com/news/lorlatinib-shows-impressive-5-year-pfs-results-in-alk-positive-advanced-nsclc 2025-05-11T16:39:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lorlatinib-shows-impressive-5-year-pfs-results-in-alk-positive-advanced-nsclc 2025-05-11T16:39:48+00:00 hourly 0.9 https://trial.medpath.com/news/inductive-bio-secures-25m-series-a-to-revolutionize-small-molecule-drug-discovery-with-ai 2025-05-11T16:39:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inductive-bio-secures-25m-series-a-to-revolutionize-small-molecule-drug-discovery-with-ai 2025-05-11T16:39:18+00:00 hourly 0.9 https://trial.medpath.com/news/tfox-regimen-shows-superior-efficacy-over-folfox-in-advanced-her2-negative-gastric-cancer 2025-05-11T16:38:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tfox-regimen-shows-superior-efficacy-over-folfox-in-advanced-her2-negative-gastric-cancer 2025-05-11T16:38:34+00:00 hourly 0.9 https://trial.medpath.com/news/givinostat-shows-promise-for-duchenne-muscular-dystrophy-as-families-push-for-broader-access 2025-05-11T16:10:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/givinostat-shows-promise-for-duchenne-muscular-dystrophy-as-families-push-for-broader-access 2025-05-11T16:10:30+00:00 hourly 0.9 https://trial.medpath.com/news/innovative-hydrogel-technologies-transform-chronic-wound-treatment-with-enhanced-healing-properties 2025-05-11T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/innovative-hydrogel-technologies-transform-chronic-wound-treatment-with-enhanced-healing-properties 2025-05-11T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/glass-house-brands-partners-with-uc-berkeley-for-groundbreaking-hemp-research-initiative 2025-05-11T12:04:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glass-house-brands-partners-with-uc-berkeley-for-groundbreaking-hemp-research-initiative 2025-05-11T12:04:51+00:00 hourly 0.9 https://trial.medpath.com/news/abcellera-s-abcl575-shows-promise-for-atopic-dermatitis-with-extended-half-life-in-preclinical-studies 2025-05-11T12:04:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abcellera-s-abcl575-shows-promise-for-atopic-dermatitis-with-extended-half-life-in-preclinical-studies 2025-05-11T12:04:50+00:00 hourly 0.9 https://trial.medpath.com/news/sivec-s-bactpac-platform-engineered-bacteria-redefining-targeted-drug-delivery-for-cancer-and-beyond 2025-05-11T08:34:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sivec-s-bactpac-platform-engineered-bacteria-redefining-targeted-drug-delivery-for-cancer-and-beyond 2025-05-11T08:34:57+00:00 hourly 0.9 https://trial.medpath.com/news/vietnam-signs-agreement-to-access-russia-s-potential-mrna-cancer-vaccine 2025-05-11T04:35:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vietnam-signs-agreement-to-access-russia-s-potential-mrna-cancer-vaccine 2025-05-11T04:35:16+00:00 hourly 0.9 https://trial.medpath.com/news/omada-health-files-for-ipo-showcasing-strong-growth-in-virtual-chronic-care-market 2025-05-11T03:05:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/omada-health-files-for-ipo-showcasing-strong-growth-in-virtual-chronic-care-market 2025-05-11T03:05:06+00:00 hourly 0.9 https://trial.medpath.com/news/biocon-announces-150-million-capital-expenditure-plan-amid-strong-q4-performance 2025-05-11T00:34:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biocon-announces-150-million-capital-expenditure-plan-amid-strong-q4-performance 2025-05-11T00:34:33+00:00 hourly 0.9 https://trial.medpath.com/news/amneal-and-apiject-partner-to-expand-us-based-sterile-injectable-manufacturing-with-advanced-bfs-technology 2025-05-11T00:34:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amneal-and-apiject-partner-to-expand-us-based-sterile-injectable-manufacturing-with-advanced-bfs-technology 2025-05-11T00:34:30+00:00 hourly 0.9 https://trial.medpath.com/news/kouper-emerges-from-stealth-with-10m-to-transform-hospital-discharge-care-transitions 2025-05-11T00:34:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kouper-emerges-from-stealth-with-10m-to-transform-hospital-discharge-care-transitions 2025-05-11T00:34:22+00:00 hourly 0.9 https://trial.medpath.com/news/johns-hopkins-study-identifies-key-immune-defects-limiting-pancreatic-cancer-immunotherapy-response 2025-05-11T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johns-hopkins-study-identifies-key-immune-defects-limiting-pancreatic-cancer-immunotherapy-response 2025-05-11T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cytel-and-nested-knowledge-partner-to-revolutionize-ai-enhanced-systematic-literature-reviews-for-healthcare-economics 2025-05-10T23:39:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cytel-and-nested-knowledge-partner-to-revolutionize-ai-enhanced-systematic-literature-reviews-for-healthcare-economics 2025-05-10T23:39:26+00:00 hourly 0.9 https://trial.medpath.com/news/adma-biologics-secures-fda-clearance-for-yield-enhancement-process-poised-for-margin-expansion-in-2026 2025-05-10T21:12:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adma-biologics-secures-fda-clearance-for-yield-enhancement-process-poised-for-margin-expansion-in-2026 2025-05-10T21:12:00+00:00 hourly 0.9 https://trial.medpath.com/news/nanyang-biologics-and-precisya-global-form-strategic-alliance-to-advance-ai-driven-natural-compound-discovery 2025-05-10T21:11:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nanyang-biologics-and-precisya-global-form-strategic-alliance-to-advance-ai-driven-natural-compound-discovery 2025-05-10T21:11:38+00:00 hourly 0.9 https://trial.medpath.com/news/cdsco-approves-novartis-protocol-amendment-for-iptacopan-study-in-rare-kidney-disorders 2025-05-10T20:39:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cdsco-approves-novartis-protocol-amendment-for-iptacopan-study-in-rare-kidney-disorders 2025-05-10T20:39:28+00:00 hourly 0.9 https://trial.medpath.com/news/eyp-1901-shows-promising-results-in-verona-trial-for-diabetic-macular-edema 2025-05-10T20:10:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eyp-1901-shows-promising-results-in-verona-trial-for-diabetic-macular-edema 2025-05-10T20:10:20+00:00 hourly 0.9 https://trial.medpath.com/news/hku-researchers-develop-breakthrough-needle-free-flu-vaccine-with-broader-protection 2025-05-10T20:09:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hku-researchers-develop-breakthrough-needle-free-flu-vaccine-with-broader-protection 2025-05-10T20:09:51+00:00 hourly 0.9 https://trial.medpath.com/news/clemson-researchers-test-existing-drugs-for-sanfilippo-syndrome-using-fruit-fly-models 2025-05-10T18:05:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clemson-researchers-test-existing-drugs-for-sanfilippo-syndrome-using-fruit-fly-models 2025-05-10T18:05:58+00:00 hourly 0.9 https://trial.medpath.com/news/healthy-extracts-secures-exclusive-rights-to-innovative-nutrient-infused-straw-technology 2025-05-10T17:41:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/healthy-extracts-secures-exclusive-rights-to-innovative-nutrient-infused-straw-technology 2025-05-10T17:41:23+00:00 hourly 0.9 https://trial.medpath.com/news/ai-designed-dna-successfully-controls-gene-expression-in-mammalian-cells-for-first-time 2025-05-10T17:10:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-designed-dna-successfully-controls-gene-expression-in-mammalian-cells-for-first-time 2025-05-10T17:10:34+00:00 hourly 0.9 https://trial.medpath.com/news/phase-3-ecog-acrin-ea4151-trial-evaluates-necessity-of-auto-hct-in-modern-mcl-treatment 2025-05-10T16:35:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-3-ecog-acrin-ea4151-trial-evaluates-necessity-of-auto-hct-in-modern-mcl-treatment 2025-05-10T16:35:48+00:00 hourly 0.9 https://trial.medpath.com/news/helios-trial-shows-promise-otx-tki-demonstrates-positive-results-for-diabetic-retinopathy-treatment 2025-05-10T16:35:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/helios-trial-shows-promise-otx-tki-demonstrates-positive-results-for-diabetic-retinopathy-treatment 2025-05-10T16:35:05+00:00 hourly 0.9 https://trial.medpath.com/news/skyline-therapeutics-to-present-novel-optogenetic-gene-therapy-for-retinitis-pigmentosa-at-asgct-2025 2025-05-10T16:35:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/skyline-therapeutics-to-present-novel-optogenetic-gene-therapy-for-retinitis-pigmentosa-at-asgct-2025 2025-05-10T16:35:04+00:00 hourly 0.9 https://trial.medpath.com/news/lithuanian-firm-delta-biosciences-to-launch-pioneering-space-pharmaceutical-stability-study-on-iss 2025-05-10T16:10:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lithuanian-firm-delta-biosciences-to-launch-pioneering-space-pharmaceutical-stability-study-on-iss 2025-05-10T16:10:27+00:00 hourly 0.9 https://trial.medpath.com/news/hawaii-secures-700-million-settlement-from-bristol-myers-squibb-and-sanofi-over-plavix-efficacy-in-diverse-populations 2025-05-10T15:11:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hawaii-secures-700-million-settlement-from-bristol-myers-squibb-and-sanofi-over-plavix-efficacy-in-diverse-populations 2025-05-10T15:11:05+00:00 hourly 0.9 https://trial.medpath.com/news/scg101-shows-dual-antiviral-and-antitumor-effects-in-hbv-related-liver-cancer-trial 2025-05-10T15:08:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scg101-shows-dual-antiviral-and-antitumor-effects-in-hbv-related-liver-cancer-trial 2025-05-10T15:08:43+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-medtech-partners-with-qure-ai-to-advance-ai-powered-lung-cancer-detection-in-india 2025-05-10T13:34:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johnson-johnson-medtech-partners-with-qure-ai-to-advance-ai-powered-lung-cancer-detection-in-india 2025-05-10T13:34:54+00:00 hourly 0.9 https://trial.medpath.com/news/trailhead-biosystems-secures-20m-to-advance-ipsc-technology-for-drug-discovery-and-regenerative-medicine 2025-05-10T12:34:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trailhead-biosystems-secures-20m-to-advance-ipsc-technology-for-drug-discovery-and-regenerative-medicine 2025-05-10T12:34:22+00:00 hourly 0.9 https://trial.medpath.com/news/thirona-and-copd-foundation-launch-major-ai-study-to-transform-copd-treatment 2025-05-10T12:34:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/thirona-and-copd-foundation-launch-major-ai-study-to-transform-copd-treatment 2025-05-10T12:34:18+00:00 hourly 0.9 https://trial.medpath.com/news/aflibercept-8-mg-shows-extended-dosing-intervals-in-real-world-namd-treatment 2025-05-10T09:04:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aflibercept-8-mg-shows-extended-dosing-intervals-in-real-world-namd-treatment 2025-05-10T09:04:54+00:00 hourly 0.9 https://trial.medpath.com/news/global-diabetes-care-market-projected-to-reach-62-73-billion-by-2032-driven-by-rising-disease-prevalence-and-technology-advances 2025-05-10T09:04:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-diabetes-care-market-projected-to-reach-62-73-billion-by-2032-driven-by-rising-disease-prevalence-and-technology-advances 2025-05-10T09:04:17+00:00 hourly 0.9 https://trial.medpath.com/news/ngex-minerals-reports-exceptional-gold-grades-in-phase-3-drilling-at-lunahuasi-project 2025-05-10T08:34:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ngex-minerals-reports-exceptional-gold-grades-in-phase-3-drilling-at-lunahuasi-project 2025-05-10T08:34:16+00:00 hourly 0.9 https://trial.medpath.com/news/lumithera-s-valeda-light-delivery-system-shows-extended-vision-benefits-in-dry-amd-patients-over-4-5-years 2025-05-10T07:34:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lumithera-s-valeda-light-delivery-system-shows-extended-vision-benefits-in-dry-amd-patients-over-4-5-years 2025-05-10T07:34:43+00:00 hourly 0.9 https://trial.medpath.com/news/nelipak-expands-healthcare-packaging-operations-in-costa-rica-with-new-60m-manufacturing-facility 2025-05-10T07:05:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nelipak-expands-healthcare-packaging-operations-in-costa-rica-with-new-60m-manufacturing-facility 2025-05-10T07:05:04+00:00 hourly 0.9 https://trial.medpath.com/news/fda-demands-additional-trial-for-novavax-covid-19-vaccine-delaying-full-approval 2025-05-10T04:39:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-demands-additional-trial-for-novavax-covid-19-vaccine-delaying-full-approval 2025-05-10T04:39:22+00:00 hourly 0.9 https://trial.medpath.com/news/aprocitentan-shows-promising-results-in-black-adults-with-resistant-hypertension 2025-05-10T04:39:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aprocitentan-shows-promising-results-in-black-adults-with-resistant-hypertension 2025-05-10T04:39:13+00:00 hourly 0.9 https://trial.medpath.com/news/avammune-therapeutics-secures-12m-series-a-funding-to-advance-novel-cancer-immunotherapy 2025-05-10T04:39:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avammune-therapeutics-secures-12m-series-a-funding-to-advance-novel-cancer-immunotherapy 2025-05-10T04:39:07+00:00 hourly 0.9 https://trial.medpath.com/news/lumithera-s-valeda-light-delivery-system-shows-sustained-vision-improvement-in-dry-amd-patients 2025-05-10T04:38:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lumithera-s-valeda-light-delivery-system-shows-sustained-vision-improvement-in-dry-amd-patients 2025-05-10T04:38:35+00:00 hourly 0.9 https://trial.medpath.com/news/tarlatamab-shows-superior-survival-in-small-cell-lung-cancer-key-highlights-from-asco-2025 2025-05-10T04:09:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tarlatamab-shows-superior-survival-in-small-cell-lung-cancer-key-highlights-from-asco-2025 2025-05-10T04:09:53+00:00 hourly 0.9 https://trial.medpath.com/news/braf-p-v600e-mutation-shows-limited-prognostic-value-in-papillary-thyroid-cancer-risk-stratification 2025-05-10T03:08:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/braf-p-v600e-mutation-shows-limited-prognostic-value-in-papillary-thyroid-cancer-risk-stratification 2025-05-10T03:08:30+00:00 hourly 0.9 https://trial.medpath.com/news/strategic-sequencing-of-t-cell-therapies-in-relapsed-refractory-multiple-myeloma-expert-guidelines 2025-05-10T02:41:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/strategic-sequencing-of-t-cell-therapies-in-relapsed-refractory-multiple-myeloma-expert-guidelines 2025-05-10T02:41:07+00:00 hourly 0.9 https://trial.medpath.com/news/taysha-gene-therapies-advances-tsha-102-for-rett-syndrome-with-fda-alignment-on-pivotal-trial-design 2025-05-10T02:40:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/taysha-gene-therapies-advances-tsha-102-for-rett-syndrome-with-fda-alignment-on-pivotal-trial-design 2025-05-10T02:40:56+00:00 hourly 0.9 https://trial.medpath.com/news/reduced-dose-radiotherapy-shows-promise-for-early-stage-anal-cancer-treatment 2025-05-10T02:05:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/reduced-dose-radiotherapy-shows-promise-for-early-stage-anal-cancer-treatment 2025-05-10T02:05:30+00:00 hourly 0.9 https://trial.medpath.com/news/new-cancer-center-at-jfk-university-medical-center-aims-to-enhance-multidisciplinary-care 2025-05-10T02:05:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-cancer-center-at-jfk-university-medical-center-aims-to-enhance-multidisciplinary-care 2025-05-10T02:05:28+00:00 hourly 0.9 https://trial.medpath.com/news/comprehensive-treatment-strategies-for-epithelioid-sarcoma-from-frontline-approaches-to-disease-progression-management 2025-05-10T02:04:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/comprehensive-treatment-strategies-for-epithelioid-sarcoma-from-frontline-approaches-to-disease-progression-management 2025-05-10T02:04:48+00:00 hourly 0.9 https://trial.medpath.com/news/newbiologix-licenses-high-yield-hek293-cell-line-to-recibiopharm-for-advanced-aav-gene-therapy-production 2025-05-10T01:10:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/newbiologix-licenses-high-yield-hek293-cell-line-to-recibiopharm-for-advanced-aav-gene-therapy-production 2025-05-10T01:10:13+00:00 hourly 0.9 https://trial.medpath.com/news/biotech-funding-crisis-forces-strategic-pivots-as-vc-investment-remains-challenging-despite-recovery-signs 2025-05-10T01:03:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biotech-funding-crisis-forces-strategic-pivots-as-vc-investment-remains-challenging-despite-recovery-signs 2025-05-10T01:03:19+00:00 hourly 0.9 https://trial.medpath.com/news/takeda-accelerates-us-investment-strategy-while-advancing-three-pivotal-phase-iii-programs-for-2025 2025-05-10T00:40:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/takeda-accelerates-us-investment-strategy-while-advancing-three-pivotal-phase-iii-programs-for-2025 2025-05-10T00:40:11+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-in-als-treatment-canadian-researchers-successfully-bypass-blood-brain-barrier 2025-05-10T00:40:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-in-als-treatment-canadian-researchers-successfully-bypass-blood-brain-barrier 2025-05-10T00:40:07+00:00 hourly 0.9 https://trial.medpath.com/news/coave-therapeutics-unveils-coaav-csf-01-a-breakthrough-gene-therapy-vector-for-cns-diseases 2025-05-10T00:39:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/coave-therapeutics-unveils-coaav-csf-01-a-breakthrough-gene-therapy-vector-for-cns-diseases 2025-05-10T00:39:20+00:00 hourly 0.9 https://trial.medpath.com/news/plozasiran-shows-promise-in-reducing-cholesterol-and-triglycerides-in-mixed-hyperlipidemia-patients 2025-05-10T00:39:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/plozasiran-shows-promise-in-reducing-cholesterol-and-triglycerides-in-mixed-hyperlipidemia-patients 2025-05-10T00:39:11+00:00 hourly 0.9 https://trial.medpath.com/news/cns-pharmaceuticals-reports-berubicin-trial-results-in-glioblastoma-patients 2025-05-10T00:39:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cns-pharmaceuticals-reports-berubicin-trial-results-in-glioblastoma-patients 2025-05-10T00:39:10+00:00 hourly 0.9 https://trial.medpath.com/news/rocket-pharmaceuticals-to-present-first-phase-1-data-for-gene-therapy-in-rare-heart-condition-at-asgct 2025-05-10T00:39:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rocket-pharmaceuticals-to-present-first-phase-1-data-for-gene-therapy-in-rare-heart-condition-at-asgct 2025-05-10T00:39:07+00:00 hourly 0.9 https://trial.medpath.com/news/applied-therapeutics-to-present-extended-inspire-trial-data-for-govorestat-in-sord-deficiency-at-pns-annual-meeting 2025-05-10T00:13:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/applied-therapeutics-to-present-extended-inspire-trial-data-for-govorestat-in-sord-deficiency-at-pns-annual-meeting 2025-05-10T00:13:03+00:00 hourly 0.9 https://trial.medpath.com/news/leucine-rich-bio-expands-global-footprint-launches-bugspeaks-gut-microbiome-test-in-qatar 2025-05-10T00:12:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/leucine-rich-bio-expands-global-footprint-launches-bugspeaks-gut-microbiome-test-in-qatar 2025-05-10T00:12:55+00:00 hourly 0.9 https://trial.medpath.com/news/biopharma-q1-updates-new-drug-launches-and-fda-extension-for-cytokinetics-aficamten 2025-05-10T00:12:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biopharma-q1-updates-new-drug-launches-and-fda-extension-for-cytokinetics-aficamten 2025-05-10T00:12:52+00:00 hourly 0.9 https://trial.medpath.com/news/digital-health-technologies-and-ai-show-promise-for-transforming-lysosomal-storage-disorder-care-in-europe 2025-05-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/digital-health-technologies-and-ai-show-promise-for-transforming-lysosomal-storage-disorder-care-in-europe 2025-05-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-initiates-pdufa-viii-reauthorization-process-with-public-meeting-and-assessment-report 2025-05-09T23:10:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-initiates-pdufa-viii-reauthorization-process-with-public-meeting-and-assessment-report 2025-05-09T23:10:23+00:00 hourly 0.9 https://trial.medpath.com/news/durvalumab-combination-shows-disease-free-survival-improvement-in-high-risk-non-muscle-invasive-bladder-cancer 2025-05-09T23:09:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/durvalumab-combination-shows-disease-free-survival-improvement-in-high-risk-non-muscle-invasive-bladder-cancer 2025-05-09T23:09:40+00:00 hourly 0.9 https://trial.medpath.com/news/new-report-reveals-trends-in-pharmaceutical-and-biotechnology-royalty-rates-from-2010-2025 2025-05-09T22:42:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-report-reveals-trends-in-pharmaceutical-and-biotechnology-royalty-rates-from-2010-2025 2025-05-09T22:42:02+00:00 hourly 0.9 https://trial.medpath.com/news/palatin-technologies-completes-1-1m-public-offering-following-otc-pink-transition 2025-05-09T22:12:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/palatin-technologies-completes-1-1m-public-offering-following-otc-pink-transition 2025-05-09T22:12:50+00:00 hourly 0.9 https://trial.medpath.com/news/nigerian-firm-codix-bio-secures-first-who-backed-license-to-manufacture-rapid-diagnostic-tests-in-africa 2025-05-09T22:12:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nigerian-firm-codix-bio-secures-first-who-backed-license-to-manufacture-rapid-diagnostic-tests-in-africa 2025-05-09T22:12:04+00:00 hourly 0.9 https://trial.medpath.com/news/nkgen-biotech-ceo-invests-2-65-million-of-personal-funds-to-advance-alzheimer-s-cell-therapy-trial 2025-05-09T21:41:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nkgen-biotech-ceo-invests-2-65-million-of-personal-funds-to-advance-alzheimer-s-cell-therapy-trial 2025-05-09T21:41:30+00:00 hourly 0.9 https://trial.medpath.com/news/singapore-s-prl3-zumab-shows-promise-in-phase-ii-trial-for-treatment-resistant-solid-tumors 2025-05-09T21:39:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/singapore-s-prl3-zumab-shows-promise-in-phase-ii-trial-for-treatment-resistant-solid-tumors 2025-05-09T21:39:18+00:00 hourly 0.9 https://trial.medpath.com/news/hillhurst-bio-secures-6-3-million-in-grants-to-advance-novel-parkinson-s-disease-treatment 2025-05-09T21:39:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hillhurst-bio-secures-6-3-million-in-grants-to-advance-novel-parkinson-s-disease-treatment 2025-05-09T21:39:15+00:00 hourly 0.9 https://trial.medpath.com/news/roche-invests-283-million-in-shanghai-biologics-facility-for-eye-disease-treatment 2025-05-09T21:09:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-invests-283-million-in-shanghai-biologics-facility-for-eye-disease-treatment 2025-05-09T21:09:59+00:00 hourly 0.9 https://trial.medpath.com/news/abvc-biopharma-secures-japanese-patent-for-botanical-depression-treatment-through-2040 2025-05-09T21:09:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abvc-biopharma-secures-japanese-patent-for-botanical-depression-treatment-through-2040 2025-05-09T21:09:22+00:00 hourly 0.9 https://trial.medpath.com/news/nuevocor-secures-us-45-million-series-b-funding-to-advance-gene-therapy-for-genetic-cardiomyopathy 2025-05-09T20:38:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nuevocor-secures-us-45-million-series-b-funding-to-advance-gene-therapy-for-genetic-cardiomyopathy 2025-05-09T20:38:58+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-opens-300-million-cell-therapy-manufacturing-facility-in-rockville-maryland 2025-05-09T20:38:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-opens-300-million-cell-therapy-manufacturing-facility-in-rockville-maryland 2025-05-09T20:38:48+00:00 hourly 0.9 https://trial.medpath.com/news/sublocade-shows-promise-as-safe-treatment-option-for-opioid-use-disorder-during-pregnancy 2025-05-09T20:37:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sublocade-shows-promise-as-safe-treatment-option-for-opioid-use-disorder-during-pregnancy 2025-05-09T20:37:50+00:00 hourly 0.9 https://trial.medpath.com/news/novel-immunotherapies-and-targeted-agents-show-promise-in-myelodysplastic-syndromes-treatment-landscape 2025-05-09T20:37:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-immunotherapies-and-targeted-agents-show-promise-in-myelodysplastic-syndromes-treatment-landscape 2025-05-09T20:37:24+00:00 hourly 0.9 https://trial.medpath.com/news/kelonia-therapeutics-to-present-novel-in-vivo-gene-delivery-system-data-at-asgct-2025 2025-05-09T20:18:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kelonia-therapeutics-to-present-novel-in-vivo-gene-delivery-system-data-at-asgct-2025 2025-05-09T20:18:40+00:00 hourly 0.9 https://trial.medpath.com/news/haic-with-folfox-plus-camrelizumab-and-sorafenib-shows-limited-efficacy-in-advanced-hcc 2025-05-09T20:17:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/haic-with-folfox-plus-camrelizumab-and-sorafenib-shows-limited-efficacy-in-advanced-hcc 2025-05-09T20:17:59+00:00 hourly 0.9 https://trial.medpath.com/news/protalix-advances-prx-115-gout-treatment-to-phase-ii-following-promising-early-results-and-strong-q1-revenue 2025-05-09T20:17:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/protalix-advances-prx-115-gout-treatment-to-phase-ii-following-promising-early-results-and-strong-q1-revenue 2025-05-09T20:17:55+00:00 hourly 0.9 https://trial.medpath.com/news/eu-proposes-critical-medicines-act-to-address-supply-chain-vulnerabilities-and-reduce-import-dependency 2025-05-09T20:15:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eu-proposes-critical-medicines-act-to-address-supply-chain-vulnerabilities-and-reduce-import-dependency 2025-05-09T20:15:13+00:00 hourly 0.9 https://trial.medpath.com/news/weightwatchers-files-for-bankruptcy-as-glp-1-weight-loss-drugs-reshape-industry 2025-05-09T19:44:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/weightwatchers-files-for-bankruptcy-as-glp-1-weight-loss-drugs-reshape-industry 2025-05-09T19:44:02+00:00 hourly 0.9 https://trial.medpath.com/news/nkure-and-crispr-therapeutics-partner-to-develop-off-the-shelf-car-t-therapy-for-cancer-in-india 2025-05-09T19:38:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nkure-and-crispr-therapeutics-partner-to-develop-off-the-shelf-car-t-therapy-for-cancer-in-india 2025-05-09T19:38:45+00:00 hourly 0.9 https://trial.medpath.com/news/shifting-landscape-5eu-markets-show-significant-changes-in-hta-decisions-and-drug-pricing-in-q1-2025 2025-05-09T19:38:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shifting-landscape-5eu-markets-show-significant-changes-in-hta-decisions-and-drug-pricing-in-q1-2025 2025-05-09T19:38:38+00:00 hourly 0.9 https://trial.medpath.com/news/systimmune-to-present-promising-data-on-iza-bren-for-her2-negative-breast-cancer-at-esmo-breast-2025 2025-05-09T19:11:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/systimmune-to-present-promising-data-on-iza-bren-for-her2-negative-breast-cancer-at-esmo-breast-2025 2025-05-09T19:11:17+00:00 hourly 0.9 https://trial.medpath.com/news/leap-therapeutics-halves-workforce-and-refocuses-cancer-drug-development-amid-market-challenges 2025-05-09T19:10:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/leap-therapeutics-halves-workforce-and-refocuses-cancer-drug-development-amid-market-challenges 2025-05-09T19:10:18+00:00 hourly 0.9 https://trial.medpath.com/news/minaris-advanced-therapies-launches-as-global-cell-therapy-cdmo-powerhouse 2025-05-09T19:10:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/minaris-advanced-therapies-launches-as-global-cell-therapy-cdmo-powerhouse 2025-05-09T19:10:14+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-reshuffles-executive-leadership-to-accelerate-global-growth-strategy 2025-05-09T18:07:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-reshuffles-executive-leadership-to-accelerate-global-growth-strategy 2025-05-09T18:07:38+00:00 hourly 0.9 https://trial.medpath.com/news/taiwan-s-formosa-pharmaceuticals-signs-exclusive-licensing-deal-with-almac-discovery-for-adc-development 2025-05-09T17:38:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/taiwan-s-formosa-pharmaceuticals-signs-exclusive-licensing-deal-with-almac-discovery-for-adc-development 2025-05-09T17:38:58+00:00 hourly 0.9 https://trial.medpath.com/news/takeda-spotlights-three-late-stage-readouts-as-potential-inflection-point-amid-vyvanse-generic-competition 2025-05-09T17:10:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/takeda-spotlights-three-late-stage-readouts-as-potential-inflection-point-amid-vyvanse-generic-competition 2025-05-09T17:10:04+00:00 hourly 0.9 https://trial.medpath.com/news/target-rwe-showcases-groundbreaking-liver-disease-research-at-easl-congress-2025 2025-05-09T16:43:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/target-rwe-showcases-groundbreaking-liver-disease-research-at-easl-congress-2025 2025-05-09T16:43:25+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-commits-250-million-to-expand-purdue-university-research-alliance-through-2032 2025-05-09T16:42:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-commits-250-million-to-expand-purdue-university-research-alliance-through-2032 2025-05-09T16:42:33+00:00 hourly 0.9 https://trial.medpath.com/news/crinecerfont-shows-promise-in-pediatric-congenital-adrenal-hyperplasia-across-all-patient-subgroups 2025-05-09T16:42:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crinecerfont-shows-promise-in-pediatric-congenital-adrenal-hyperplasia-across-all-patient-subgroups 2025-05-09T16:42:26+00:00 hourly 0.9 https://trial.medpath.com/news/minghui-and-qilu-pharmaceuticals-partner-on-b7-h3-adc-development-in-210-million-deal-for-greater-china 2025-05-09T16:42:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/minghui-and-qilu-pharmaceuticals-partner-on-b7-h3-adc-development-in-210-million-deal-for-greater-china 2025-05-09T16:42:12+00:00 hourly 0.9 https://trial.medpath.com/news/galimedix-advances-oral-gal-101-therapy-for-alzheimer-s-and-eye-diseases-in-phase-1-trial 2025-05-09T16:42:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/galimedix-advances-oral-gal-101-therapy-for-alzheimer-s-and-eye-diseases-in-phase-1-trial 2025-05-09T16:42:00+00:00 hourly 0.9 https://trial.medpath.com/news/perfuse-therapeutics-per-001-shows-promise-as-first-disease-modifying-treatment-for-glaucoma-in-phase-1-2a-trial 2025-05-09T16:41:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/perfuse-therapeutics-per-001-shows-promise-as-first-disease-modifying-treatment-for-glaucoma-in-phase-1-2a-trial 2025-05-09T16:41:56+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-study-validates-decisiondx-um-test-with-prame-biomarker-for-improved-uveal-melanoma-risk-stratification 2025-05-09T16:41:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-study-validates-decisiondx-um-test-with-prame-biomarker-for-improved-uveal-melanoma-risk-stratification 2025-05-09T16:41:47+00:00 hourly 0.9 https://trial.medpath.com/news/genefab-and-regcell-partner-to-advance-novel-treg-cell-therapy-for-autoimmune-diseases-into-us-clinical-trials 2025-05-09T16:41:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genefab-and-regcell-partner-to-advance-novel-treg-cell-therapy-for-autoimmune-diseases-into-us-clinical-trials 2025-05-09T16:41:43+00:00 hourly 0.9 https://trial.medpath.com/news/lilly-and-purdue-university-forge-historic-250-million-pharmaceutical-innovation-partnership 2025-05-09T16:40:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lilly-and-purdue-university-forge-historic-250-million-pharmaceutical-innovation-partnership 2025-05-09T16:40:41+00:00 hourly 0.9 https://trial.medpath.com/news/formosa-pharmaceuticals-secures-exclusive-license-for-novel-bispecific-adc-targeting-egfr-ror1-solid-tumors 2025-05-09T16:40:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/formosa-pharmaceuticals-secures-exclusive-license-for-novel-bispecific-adc-targeting-egfr-ror1-solid-tumors 2025-05-09T16:40:40+00:00 hourly 0.9 https://trial.medpath.com/news/insilico-medicine-secures-123-million-series-e-funding-to-advance-ai-driven-drug-discovery-pipeline 2025-05-09T16:40:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/insilico-medicine-secures-123-million-series-e-funding-to-advance-ai-driven-drug-discovery-pipeline 2025-05-09T16:40:12+00:00 hourly 0.9 https://trial.medpath.com/news/sirius-therapeutics-secures-50-million-in-series-b2-funding-to-advance-sirna-therapies-for-cardiometabolic-diseases 2025-05-09T16:40:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sirius-therapeutics-secures-50-million-in-series-b2-funding-to-advance-sirna-therapies-for-cardiometabolic-diseases 2025-05-09T16:40:09+00:00 hourly 0.9 https://trial.medpath.com/news/new-abiraterone-formulation-shows-equivalent-efficacy-at-lower-dose-for-metastatic-prostate-cancer 2025-05-09T16:39:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-abiraterone-formulation-shows-equivalent-efficacy-at-lower-dose-for-metastatic-prostate-cancer 2025-05-09T16:39:36+00:00 hourly 0.9 https://trial.medpath.com/news/omrx-oncology-launches-phase-2-trial-of-novel-oral-pd-l1-inhibitor-for-nsclc-targeting-global-access-disparities 2025-05-09T16:39:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/omrx-oncology-launches-phase-2-trial-of-novel-oral-pd-l1-inhibitor-for-nsclc-targeting-global-access-disparities 2025-05-09T16:39:34+00:00 hourly 0.9 https://trial.medpath.com/news/east-africa-launches-regional-drug-research-hub-in-kenya-and-expands-health-security-network 2025-05-09T16:39:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/east-africa-launches-regional-drug-research-hub-in-kenya-and-expands-health-security-network 2025-05-09T16:39:32+00:00 hourly 0.9 https://trial.medpath.com/news/neoadjuvant-scrt-plus-camrelizumab-shows-promising-3-year-survival-in-locally-advanced-rectal-cancer 2025-05-09T16:39:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neoadjuvant-scrt-plus-camrelizumab-shows-promising-3-year-survival-in-locally-advanced-rectal-cancer 2025-05-09T16:39:29+00:00 hourly 0.9 https://trial.medpath.com/news/path-ex-secures-5-million-to-advance-novel-sepsis-treatment-device-cyclope 2025-05-09T16:39:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/path-ex-secures-5-million-to-advance-novel-sepsis-treatment-device-cyclope 2025-05-09T16:39:16+00:00 hourly 0.9 https://trial.medpath.com/news/quanthealth-launches-first-clinical-trial-foundation-model-on-aws-marketplace 2025-05-09T16:39:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quanthealth-launches-first-clinical-trial-foundation-model-on-aws-marketplace 2025-05-09T16:39:11+00:00 hourly 0.9 https://trial.medpath.com/news/think-bioscience-and-crystalsfirst-expand-partnership-to-tackle-undruggable-targets 2025-05-09T16:39:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/think-bioscience-and-crystalsfirst-expand-partnership-to-tackle-undruggable-targets 2025-05-09T16:39:09+00:00 hourly 0.9 https://trial.medpath.com/news/fda-misses-review-deadline-for-gsk-s-nucala-copd-expansion-amid-regulatory-delays 2025-05-09T16:38:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-misses-review-deadline-for-gsk-s-nucala-copd-expansion-amid-regulatory-delays 2025-05-09T16:38:56+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-at-home-cervical-cancer-screening-test-expanding-access-to-preventive-care 2025-05-09T16:04:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-at-home-cervical-cancer-screening-test-expanding-access-to-preventive-care 2025-05-09T16:04:37+00:00 hourly 0.9 https://trial.medpath.com/news/indonesia-launches-phase-3-trial-of-m72-tuberculosis-vaccine-amid-safety-assurances 2025-05-09T15:57:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/indonesia-launches-phase-3-trial-of-m72-tuberculosis-vaccine-amid-safety-assurances 2025-05-09T15:57:21+00:00 hourly 0.9 https://trial.medpath.com/news/optigo-biotherapeutics-develops-long-acting-anti-vegf-therapy-with-six-month-dosing-potential 2025-05-09T15:07:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/optigo-biotherapeutics-develops-long-acting-anti-vegf-therapy-with-six-month-dosing-potential 2025-05-09T15:07:06+00:00 hourly 0.9 https://trial.medpath.com/news/lilly-s-oral-glp-1-orforglipron-shows-promising-results-in-phase-3-trial 2025-05-09T14:38:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lilly-s-oral-glp-1-orforglipron-shows-promising-results-in-phase-3-trial 2025-05-09T14:38:34+00:00 hourly 0.9 https://trial.medpath.com/news/leo-pharma-s-temtokibart-shows-promising-results-in-phase-2b-trial-for-moderate-to-severe-atopic-dermatitis 2025-05-09T13:38:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/leo-pharma-s-temtokibart-shows-promising-results-in-phase-2b-trial-for-moderate-to-severe-atopic-dermatitis 2025-05-09T13:38:59+00:00 hourly 0.9 https://trial.medpath.com/news/ema-suspends-ixchiq-chikungunya-vaccine-for-elderly-following-safety-concerns 2025-05-09T13:38:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-suspends-ixchiq-chikungunya-vaccine-for-elderly-following-safety-concerns 2025-05-09T13:38:27+00:00 hourly 0.9 https://trial.medpath.com/news/bombay-hc-challenges-cdsco-s-rejection-of-indigenous-cancer-immunotherapy-trial 2025-05-09T12:36:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bombay-hc-challenges-cdsco-s-rejection-of-indigenous-cancer-immunotherapy-trial 2025-05-09T12:36:19+00:00 hourly 0.9 https://trial.medpath.com/news/pharmac-to-fund-advanced-melanoma-treatments-in-new-zealand-starting-june-2025 2025-05-09T12:36:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharmac-to-fund-advanced-melanoma-treatments-in-new-zealand-starting-june-2025 2025-05-09T12:36:17+00:00 hourly 0.9 https://trial.medpath.com/news/novagold-completes-179-million-public-offering-to-advance-donlin-gold-project-development 2025-05-09T11:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novagold-completes-179-million-public-offering-to-advance-donlin-gold-project-development 2025-05-09T11:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/biowell-partners-with-texas-biotechnology-to-create-largest-public-industrial-biomanufacturing-facility-in-the-us 2025-05-09T10:35:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biowell-partners-with-texas-biotechnology-to-create-largest-public-industrial-biomanufacturing-facility-in-the-us 2025-05-09T10:35:46+00:00 hourly 0.9 https://trial.medpath.com/news/neurofibromatoses-pipeline-shows-strong-activity-with-12-therapies-in-development-across-multiple-clinical-stages 2025-05-09T10:09:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neurofibromatoses-pipeline-shows-strong-activity-with-12-therapies-in-development-across-multiple-clinical-stages 2025-05-09T10:09:45+00:00 hourly 0.9 https://trial.medpath.com/news/rectify-pharma-s-novel-dual-targeted-pfm-shows-promise-for-hepatobiliary-diseases-at-easl-2025 2025-05-09T10:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rectify-pharma-s-novel-dual-targeted-pfm-shows-promise-for-hepatobiliary-diseases-at-easl-2025 2025-05-09T10:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/australian-scientists-develop-breakthrough-mrna-vaccine-strategy-for-decades-long-immunity 2025-05-09T09:40:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/australian-scientists-develop-breakthrough-mrna-vaccine-strategy-for-decades-long-immunity 2025-05-09T09:40:17+00:00 hourly 0.9 https://trial.medpath.com/news/ascidian-therapeutics-advances-rna-exon-editing-platform-with-key-leadership-appointments-and-clinical-progress 2025-05-09T09:07:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ascidian-therapeutics-advances-rna-exon-editing-platform-with-key-leadership-appointments-and-clinical-progress 2025-05-09T09:07:49+00:00 hourly 0.9 https://trial.medpath.com/news/lenz-therapeutics-and-lotus-pharmaceutical-forge-125-million-deal-for-presbyopia-treatment-in-southeast-asia 2025-05-09T09:03:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lenz-therapeutics-and-lotus-pharmaceutical-forge-125-million-deal-for-presbyopia-treatment-in-southeast-asia 2025-05-09T09:03:00+00:00 hourly 0.9 https://trial.medpath.com/news/diabetes-drug-pioglitazone-shows-promising-anti-tumor-effects-in-prostate-cancer 2025-05-09T08:38:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/diabetes-drug-pioglitazone-shows-promising-anti-tumor-effects-in-prostate-cancer 2025-05-09T08:38:39+00:00 hourly 0.9 https://trial.medpath.com/news/aribio-and-fujirebio-complete-major-biomarker-sample-collection-for-alzheimer-s-research-in-phase-3-polaris-ad-trial 2025-05-09T08:37:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aribio-and-fujirebio-complete-major-biomarker-sample-collection-for-alzheimer-s-research-in-phase-3-polaris-ad-trial 2025-05-09T08:37:55+00:00 hourly 0.9 https://trial.medpath.com/news/queen-mary-researchers-develop-novel-model-for-recurrent-glioblastoma-treatment-using-repurposed-antiparasitic-drug 2025-05-09T08:34:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/queen-mary-researchers-develop-novel-model-for-recurrent-glioblastoma-treatment-using-repurposed-antiparasitic-drug 2025-05-09T08:34:17+00:00 hourly 0.9 https://trial.medpath.com/news/ucb-s-rystiggo-r-rozanolixizumab-approved-in-japan-for-at-home-self-administration-in-gmg-patients 2025-05-09T08:13:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ucb-s-rystiggo-r-rozanolixizumab-approved-in-japan-for-at-home-self-administration-in-gmg-patients 2025-05-09T08:13:06+00:00 hourly 0.9 https://trial.medpath.com/news/rocket-pharmaceuticals-advances-gene-therapy-pipeline-with-key-updates-on-danon-disease-and-pkp2-acm-programs 2025-05-09T08:12:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rocket-pharmaceuticals-advances-gene-therapy-pipeline-with-key-updates-on-danon-disease-and-pkp2-acm-programs 2025-05-09T08:12:08+00:00 hourly 0.9 https://trial.medpath.com/news/ai-powered-pathology-transforming-cancer-diagnostics-and-precision-oncology 2025-05-09T08:11:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-powered-pathology-transforming-cancer-diagnostics-and-precision-oncology 2025-05-09T08:11:16+00:00 hourly 0.9 https://trial.medpath.com/news/shionogi-to-acquire-japan-tobacco-s-pharmaceutical-subsidiaries-for-1-1-billion 2025-05-09T08:01:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shionogi-to-acquire-japan-tobacco-s-pharmaceutical-subsidiaries-for-1-1-billion 2025-05-09T08:01:33+00:00 hourly 0.9 https://trial.medpath.com/news/nice-opens-consultations-for-two-targeted-therapies-in-advanced-non-small-cell-lung-cancer 2025-05-09T07:48:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nice-opens-consultations-for-two-targeted-therapies-in-advanced-non-small-cell-lung-cancer 2025-05-09T07:48:00+00:00 hourly 0.9 https://trial.medpath.com/news/vivo-capital-secures-740-million-for-third-cycle-of-healthcare-investment-fund 2025-05-09T07:39:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vivo-capital-secures-740-million-for-third-cycle-of-healthcare-investment-fund 2025-05-09T07:39:06+00:00 hourly 0.9 https://trial.medpath.com/news/elutia-announces-strong-first-quarter-2025-financial-results-driven-by-84-sequential-growth-in-eluprotm-sales 2025-05-09T07:10:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elutia-announces-strong-first-quarter-2025-financial-results-driven-by-84-sequential-growth-in-eluprotm-sales 2025-05-09T07:10:17+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-s-linerixibat-shows-significant-improvement-in-cholestatic-pruritus-for-primary-biliary-cholangitis-patients 2025-05-09T06:32:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-s-linerixibat-shows-significant-improvement-in-cholestatic-pruritus-for-primary-biliary-cholangitis-patients 2025-05-09T06:32:15+00:00 hourly 0.9 https://trial.medpath.com/news/novel-blood-test-could-guide-precision-treatment-for-resistant-lupus-with-rituximab-belimumab-combination 2025-05-09T06:11:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-blood-test-could-guide-precision-treatment-for-resistant-lupus-with-rituximab-belimumab-combination 2025-05-09T06:11:35+00:00 hourly 0.9 https://trial.medpath.com/news/upmc-enterprises-leads-18-25-million-series-b1-investment-in-carta-healthcare-for-ai-powered-clinical-data-management 2025-05-09T06:11:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/upmc-enterprises-leads-18-25-million-series-b1-investment-in-carta-healthcare-for-ai-powered-clinical-data-management 2025-05-09T06:11:03+00:00 hourly 0.9 https://trial.medpath.com/news/vor-bio-halts-clinical-operations-and-explores-strategic-alternatives-amid-financial-challenges 2025-05-09T06:10:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vor-bio-halts-clinical-operations-and-explores-strategic-alternatives-amid-financial-challenges 2025-05-09T06:10:26+00:00 hourly 0.9 https://trial.medpath.com/news/ludwig-enterprises-unveils-revealia-breast-a-revolutionary-cheek-swab-test-for-early-breast-cancer-detection 2025-05-09T06:08:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ludwig-enterprises-unveils-revealia-breast-a-revolutionary-cheek-swab-test-for-early-breast-cancer-detection 2025-05-09T06:08:47+00:00 hourly 0.9 https://trial.medpath.com/news/ionq-expands-quantum-computing-portfolio-through-strategic-acquisitions-of-lightsynq-and-id-quantique 2025-05-09T05:54:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ionq-expands-quantum-computing-portfolio-through-strategic-acquisitions-of-lightsynq-and-id-quantique 2025-05-09T05:54:00+00:00 hourly 0.9 https://trial.medpath.com/news/cb-scientific-rebrands-as-cardiac-biotech-solutions-advances-mycardia-at-cardiac-monitor-global-rollout 2025-05-09T05:38:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cb-scientific-rebrands-as-cardiac-biotech-solutions-advances-mycardia-at-cardiac-monitor-global-rollout 2025-05-09T05:38:22+00:00 hourly 0.9 https://trial.medpath.com/news/merck-animal-health-commits-895-million-to-expand-kansas-manufacturing-and-r-d-facilities 2025-05-09T05:11:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-animal-health-commits-895-million-to-expand-kansas-manufacturing-and-r-d-facilities 2025-05-09T05:11:58+00:00 hourly 0.9 https://trial.medpath.com/news/paq-therapeutics-secures-39m-series-b-funding-and-launches-phase-1-trial-for-novel-kras-g12d-degrader 2025-05-09T05:08:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/paq-therapeutics-secures-39m-series-b-funding-and-launches-phase-1-trial-for-novel-kras-g12d-degrader 2025-05-09T05:08:09+00:00 hourly 0.9 https://trial.medpath.com/news/disc-medicine-advances-bitopertin-nda-for-erythropoietic-protoporphyria-as-pipeline-progress-continues 2025-05-09T04:41:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/disc-medicine-advances-bitopertin-nda-for-erythropoietic-protoporphyria-as-pipeline-progress-continues 2025-05-09T04:41:47+00:00 hourly 0.9 https://trial.medpath.com/news/five-leading-companies-form-lnp-alliance-to-accelerate-nanoparticle-based-drug-development 2025-05-09T04:39:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/five-leading-companies-form-lnp-alliance-to-accelerate-nanoparticle-based-drug-development 2025-05-09T04:39:46+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-urgent-warning-against-gas-station-heroin-tianeptine-citing-severe-health-risks 2025-05-09T04:39:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-urgent-warning-against-gas-station-heroin-tianeptine-citing-severe-health-risks 2025-05-09T04:39:40+00:00 hourly 0.9 https://trial.medpath.com/news/redesign-health-and-cedars-sinai-form-strategic-partnership-to-launch-multiple-healthcare-companies 2025-05-09T04:39:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/redesign-health-and-cedars-sinai-form-strategic-partnership-to-launch-multiple-healthcare-companies 2025-05-09T04:39:23+00:00 hourly 0.9 https://trial.medpath.com/news/shionogi-and-cilcare-partner-in-eur400m-deal-to-develop-novel-hearing-loss-treatments 2025-05-09T04:37:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shionogi-and-cilcare-partner-in-eur400m-deal-to-develop-novel-hearing-loss-treatments 2025-05-09T04:37:56+00:00 hourly 0.9 https://trial.medpath.com/news/takeda-pledges-30b-in-u-s-argues-against-trumps-most-favored-nations-proposal 2025-05-09T04:37:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/takeda-pledges-30b-in-u-s-argues-against-trumps-most-favored-nations-proposal 2025-05-09T04:37:50+00:00 hourly 0.9 https://trial.medpath.com/news/tfs-healthscience-and-oncomatryx-advance-novel-fap-adc-to-phase-ib-trial-for-pancreatic-cancer 2025-05-09T04:10:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tfs-healthscience-and-oncomatryx-advance-novel-fap-adc-to-phase-ib-trial-for-pancreatic-cancer 2025-05-09T04:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/appeals-court-rejects-astrazeneca-s-challenge-to-medicare-drug-price-negotiation-program 2025-05-09T04:09:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/appeals-court-rejects-astrazeneca-s-challenge-to-medicare-drug-price-negotiation-program 2025-05-09T04:09:29+00:00 hourly 0.9 https://trial.medpath.com/news/osaka-university-develops-promising-immune-cell-therapy-for-acute-myeloid-leukemia 2025-05-09T04:09:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/osaka-university-develops-promising-immune-cell-therapy-for-acute-myeloid-leukemia 2025-05-09T04:09:28+00:00 hourly 0.9 https://trial.medpath.com/news/new-challenges-emerge-in-transitioning-cidp-patients-from-ivig-to-efgartigimod 2025-05-09T04:08:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-challenges-emerge-in-transitioning-cidp-patients-from-ivig-to-efgartigimod 2025-05-09T04:08:10+00:00 hourly 0.9 https://trial.medpath.com/news/sigachi-industries-secures-european-certification-for-metformin-hydrochloride-api 2025-05-09T04:08:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sigachi-industries-secures-european-certification-for-metformin-hydrochloride-api 2025-05-09T04:08:01+00:00 hourly 0.9 https://trial.medpath.com/news/nppa-sets-retail-prices-for-84-drugs-including-empagliflozin-combinations-following-patent-expiry 2025-05-09T04:07:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nppa-sets-retail-prices-for-84-drugs-including-empagliflozin-combinations-following-patent-expiry 2025-05-09T04:07:43+00:00 hourly 0.9 https://trial.medpath.com/news/ingenus-pharmaceuticals-advances-cancer-drug-patent-suit-against-nexus-court-dismisses-co-plaintiff 2025-05-09T04:07:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ingenus-pharmaceuticals-advances-cancer-drug-patent-suit-against-nexus-court-dismisses-co-plaintiff 2025-05-09T04:07:41+00:00 hourly 0.9 https://trial.medpath.com/news/karma-biosciences-files-patents-for-rapid-acting-nasal-pde-5-inhibitors-with-5-minute-onset 2025-05-09T04:07:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/karma-biosciences-files-patents-for-rapid-acting-nasal-pde-5-inhibitors-with-5-minute-onset 2025-05-09T04:07:40+00:00 hourly 0.9 https://trial.medpath.com/news/biovaxys-and-sona-nanotech-partner-to-develop-novel-cancer-immunotherapy-combining-dpx-platform-with-gold-nanorod-technology 2025-05-09T04:07:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biovaxys-and-sona-nanotech-partner-to-develop-novel-cancer-immunotherapy-combining-dpx-platform-with-gold-nanorod-technology 2025-05-09T04:07:20+00:00 hourly 0.9 https://trial.medpath.com/news/genezen-and-optieum-partner-to-manufacture-lentiviral-vectors-for-novel-glioblastoma-car-t-therapy 2025-05-09T04:06:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genezen-and-optieum-partner-to-manufacture-lentiviral-vectors-for-novel-glioblastoma-car-t-therapy 2025-05-09T04:06:40+00:00 hourly 0.9 https://trial.medpath.com/news/dawn-health-secures-eur11-5-million-to-expand-pharma-focused-digital-health-platform 2025-05-09T04:06:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dawn-health-secures-eur11-5-million-to-expand-pharma-focused-digital-health-platform 2025-05-09T04:06:35+00:00 hourly 0.9 https://trial.medpath.com/news/leqvio-emerges-as-leading-pcsk9-inhibitor-in-cholesterol-management-across-major-markets 2025-05-09T04:06:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/leqvio-emerges-as-leading-pcsk9-inhibitor-in-cholesterol-management-across-major-markets 2025-05-09T04:06:29+00:00 hourly 0.9 https://trial.medpath.com/news/biocon-reports-15-revenue-growth-in-q4fy25-launches-fifth-biosimilar-in-u-s-market 2025-05-09T04:06:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biocon-reports-15-revenue-growth-in-q4fy25-launches-fifth-biosimilar-in-u-s-market 2025-05-09T04:06:16+00:00 hourly 0.9 https://trial.medpath.com/news/nuvalent-advances-toward-first-nda-submission-with-pivotal-data-expected-for-ros1-and-alk-inhibitors-in-2025 2025-05-09T04:06:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nuvalent-advances-toward-first-nda-submission-with-pivotal-data-expected-for-ros1-and-alk-inhibitors-in-2025 2025-05-09T04:06:08+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-schedules-investor-conference-presentations-for-may-and-june-2025 2025-05-09T04:04:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moderna-schedules-investor-conference-presentations-for-may-and-june-2025 2025-05-09T04:04:58+00:00 hourly 0.9 https://trial.medpath.com/news/peptone-and-evotec-form-strategic-alliance-to-develop-novel-therapeutics-targeting-intrinsically-disordered-proteins 2025-05-09T04:04:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/peptone-and-evotec-form-strategic-alliance-to-develop-novel-therapeutics-targeting-intrinsically-disordered-proteins 2025-05-09T04:04:57+00:00 hourly 0.9 https://trial.medpath.com/news/schrodinger-reports-63-revenue-growth-in-q1-2025-prepares-to-share-clinical-data-for-sgr-1505 2025-05-09T04:04:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/schrodinger-reports-63-revenue-growth-in-q1-2025-prepares-to-share-clinical-data-for-sgr-1505 2025-05-09T04:04:21+00:00 hourly 0.9 https://trial.medpath.com/news/lexaria-bioscience-advances-dehydratech-platform-to-enhance-glp-1-drug-effectiveness 2025-05-09T04:04:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lexaria-bioscience-advances-dehydratech-platform-to-enhance-glp-1-drug-effectiveness 2025-05-09T04:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/10-year-data-confirms-1-week-radiotherapy-as-effective-as-3-week-course-for-early-stage-breast-cancer 2025-05-09T01:34:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/10-year-data-confirms-1-week-radiotherapy-as-effective-as-3-week-course-for-early-stage-breast-cancer 2025-05-09T01:34:56+00:00 hourly 0.9 https://trial.medpath.com/news/uic-researchers-develop-groundbreaking-antibiotic-against-superbugs-as-illinois-faces-rising-antimicrobial-resistance 2025-05-09T01:34:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uic-researchers-develop-groundbreaking-antibiotic-against-superbugs-as-illinois-faces-rising-antimicrobial-resistance 2025-05-09T01:34:54+00:00 hourly 0.9 https://trial.medpath.com/news/utr-therapeutics-submits-ind-for-novel-mrna-destabilizing-drug-targeting-c-myc-in-multiple-cancers 2025-05-09T01:34:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/utr-therapeutics-submits-ind-for-novel-mrna-destabilizing-drug-targeting-c-myc-in-multiple-cancers 2025-05-09T01:34:48+00:00 hourly 0.9 https://trial.medpath.com/news/viatris-advances-fast-acting-meloxicam-toward-fda-submission-following-successful-phase-iii-trials 2025-05-09T01:34:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/viatris-advances-fast-acting-meloxicam-toward-fda-submission-following-successful-phase-iii-trials 2025-05-09T01:34:04+00:00 hourly 0.9 https://trial.medpath.com/news/novel-myh9-gene-variant-identified-in-chinese-child-with-rare-hereditary-thrombocytopenia 2025-05-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-myh9-gene-variant-identified-in-chinese-child-with-rare-hereditary-thrombocytopenia 2025-05-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/hilo-secures-42-million-series-b-funding-to-revolutionize-blood-pressure-monitoring 2025-05-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hilo-secures-42-million-series-b-funding-to-revolutionize-blood-pressure-monitoring 2025-05-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-contact-force-sensing-pulsed-field-ablation-catheter-shows-promise-in-paroxysmal-af-treatment 2025-05-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-contact-force-sensing-pulsed-field-ablation-catheter-shows-promise-in-paroxysmal-af-treatment 2025-05-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/neurofibromatosis-type-1-with-plexiform-neurofibromas-diagnosis-epidemiology-and-clinical-manifestations 2025-05-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neurofibromatosis-type-1-with-plexiform-neurofibromas-diagnosis-epidemiology-and-clinical-manifestations 2025-05-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-commissioner-signals-shift-in-covid-19-booster-strategy-requiring-stronger-clinical-evidence 2025-05-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-commissioner-signals-shift-in-covid-19-booster-strategy-requiring-stronger-clinical-evidence 2025-05-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/pharma-leadership-shuffle-key-executive-moves-in-early-2025-reshape-industry-landscape 2025-05-08T23:33:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharma-leadership-shuffle-key-executive-moves-in-early-2025-reshape-industry-landscape 2025-05-08T23:33:16+00:00 hourly 0.9 https://trial.medpath.com/news/hyperuricemia-pipeline-shows-promise-with-15-emerging-therapies-in-development 2025-05-08T22:41:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hyperuricemia-pipeline-shows-promise-with-15-emerging-therapies-in-development 2025-05-08T22:41:00+00:00 hourly 0.9 https://trial.medpath.com/news/hepatitis-d-pipeline-shows-strong-progress-with-multiple-fda-breakthrough-designations-and-promising-phase-3-results 2025-05-08T22:40:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hepatitis-d-pipeline-shows-strong-progress-with-multiple-fda-breakthrough-designations-and-promising-phase-3-results 2025-05-08T22:40:58+00:00 hourly 0.9 https://trial.medpath.com/news/lupus-nephritis-market-expected-to-grow-as-novel-therapies-enter-clinical-trials 2025-05-08T22:40:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lupus-nephritis-market-expected-to-grow-as-novel-therapies-enter-clinical-trials 2025-05-08T22:40:56+00:00 hourly 0.9 https://trial.medpath.com/news/fda-to-deploy-ai-assistant-across-all-centers-by-june-30-to-accelerate-scientific-reviews 2025-05-08T22:39:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-to-deploy-ai-assistant-across-all-centers-by-june-30-to-accelerate-scientific-reviews 2025-05-08T22:39:50+00:00 hourly 0.9 https://trial.medpath.com/news/adavosertib-shows-promise-in-uterine-serous-carcinoma-despite-tolerability-challenges 2025-05-08T22:39:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adavosertib-shows-promise-in-uterine-serous-carcinoma-despite-tolerability-challenges 2025-05-08T22:39:28+00:00 hourly 0.9 https://trial.medpath.com/news/fast-forward-trial-one-week-breast-cancer-radiotherapy-proven-equally-effective-as-three-week-standard 2025-05-08T21:15:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fast-forward-trial-one-week-breast-cancer-radiotherapy-proven-equally-effective-as-three-week-standard 2025-05-08T21:15:12+00:00 hourly 0.9 https://trial.medpath.com/news/apimeds-pharmaceuticals-raises-13-5-million-in-ipo-for-bee-venom-based-therapy-development 2025-05-08T21:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/apimeds-pharmaceuticals-raises-13-5-million-in-ipo-for-bee-venom-based-therapy-development 2025-05-08T21:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/signatera-ctdna-test-predicts-recurrence-risk-in-high-risk-breast-cancer-patients-i-spy-2-trial-data-shows 2025-05-08T19:37:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/signatera-ctdna-test-predicts-recurrence-risk-in-high-risk-breast-cancer-patients-i-spy-2-trial-data-shows 2025-05-08T19:37:28+00:00 hourly 0.9 https://trial.medpath.com/news/panitumumab-plus-folfox-significantly-improves-survival-in-ras-braf-wild-type-locally-advanced-colon-cancer 2025-05-08T19:35:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/panitumumab-plus-folfox-significantly-improves-survival-in-ras-braf-wild-type-locally-advanced-colon-cancer 2025-05-08T19:35:58+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-miplyffa-for-niemann-pick-type-c-disease-offering-new-hope-for-rare-genetic-disorder 2025-05-08T19:35:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-miplyffa-for-niemann-pick-type-c-disease-offering-new-hope-for-rare-genetic-disorder 2025-05-08T19:35:46+00:00 hourly 0.9 https://trial.medpath.com/news/hiv-drugs-show-promising-potential-to-reduce-alzheimer-s-risk-by-up-to-13-annually 2025-05-08T19:34:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hiv-drugs-show-promising-potential-to-reduce-alzheimer-s-risk-by-up-to-13-annually 2025-05-08T19:34:39+00:00 hourly 0.9 https://trial.medpath.com/news/oryzon-genomics-secures-eur13-26-million-eu-grant-for-rare-disease-research 2025-05-08T17:37:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oryzon-genomics-secures-eur13-26-million-eu-grant-for-rare-disease-research 2025-05-08T17:37:58+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-wireless-device-enables-remote-activation-of-light-sensitive-drugs-for-pain-management 2025-05-08T17:37:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-wireless-device-enables-remote-activation-of-light-sensitive-drugs-for-pain-management 2025-05-08T17:37:46+00:00 hourly 0.9 https://trial.medpath.com/news/junshi-biosciences-receives-ind-approval-for-novel-bispecific-adc-targeting-egfr-and-her3 2025-05-08T17:37:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/junshi-biosciences-receives-ind-approval-for-novel-bispecific-adc-targeting-egfr-and-her3 2025-05-08T17:37:45+00:00 hourly 0.9 https://trial.medpath.com/news/ucla-study-advanced-mri-and-focal-therapy-revolutionize-prostate-cancer-surveillance 2025-05-08T17:21:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ucla-study-advanced-mri-and-focal-therapy-revolutionize-prostate-cancer-surveillance 2025-05-08T17:21:40+00:00 hourly 0.9 https://trial.medpath.com/news/haya-therapeutics-secures-65m-to-develop-drugs-targeting-the-dark-genome 2025-05-08T17:08:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/haya-therapeutics-secures-65m-to-develop-drugs-targeting-the-dark-genome 2025-05-08T17:08:42+00:00 hourly 0.9 https://trial.medpath.com/news/vintabio-showcases-high-efficiency-aav-vector-production-platform-at-asgct-2025 2025-05-08T17:08:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vintabio-showcases-high-efficiency-aav-vector-production-platform-at-asgct-2025 2025-05-08T17:08:25+00:00 hourly 0.9 https://trial.medpath.com/news/eu-regulator-confirms-suicidal-thoughts-as-rare-side-effect-of-hair-loss-drug-finasteride 2025-05-08T17:08:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eu-regulator-confirms-suicidal-thoughts-as-rare-side-effect-of-hair-loss-drug-finasteride 2025-05-08T17:08:19+00:00 hourly 0.9 https://trial.medpath.com/news/alphagen-intelligence-corp-announces-195000-private-placement-for-working-capital 2025-05-08T16:47:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alphagen-intelligence-corp-announces-195000-private-placement-for-working-capital 2025-05-08T16:47:00+00:00 hourly 0.9 https://trial.medpath.com/news/bioarctic-expands-exidavnemab-phase-2a-trial-to-include-multiple-system-atrophy-patients 2025-05-08T16:39:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioarctic-expands-exidavnemab-phase-2a-trial-to-include-multiple-system-atrophy-patients 2025-05-08T16:39:13+00:00 hourly 0.9 https://trial.medpath.com/news/viatris-reports-q1-2025-results-pipeline-progress-despite-financial-challenges 2025-05-08T16:39:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/viatris-reports-q1-2025-results-pipeline-progress-despite-financial-challenges 2025-05-08T16:39:05+00:00 hourly 0.9 https://trial.medpath.com/news/haya-therapeutics-secures-65-million-series-a-to-advance-rna-guided-medicines-targeting-the-dark-genome 2025-05-08T16:37:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/haya-therapeutics-secures-65-million-series-a-to-advance-rna-guided-medicines-targeting-the-dark-genome 2025-05-08T16:37:25+00:00 hourly 0.9 https://trial.medpath.com/news/crenessity-shows-consistent-efficacy-across-pediatric-cah-subgroups-while-reducing-glucocorticoid-doses 2025-05-08T16:37:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crenessity-shows-consistent-efficacy-across-pediatric-cah-subgroups-while-reducing-glucocorticoid-doses 2025-05-08T16:37:14+00:00 hourly 0.9 https://trial.medpath.com/news/yamo-pharmaceuticals-reports-breakthrough-phase-2-results-for-novel-autism-treatment-l1-79 2025-05-08T16:36:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/yamo-pharmaceuticals-reports-breakthrough-phase-2-results-for-novel-autism-treatment-l1-79 2025-05-08T16:36:06+00:00 hourly 0.9 https://trial.medpath.com/news/cytophage-secures-canadian-regulatory-approval-for-novel-phage-therapy-targeting-prosthetic-joint-infections 2025-05-08T16:36:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cytophage-secures-canadian-regulatory-approval-for-novel-phage-therapy-targeting-prosthetic-joint-infections 2025-05-08T16:36:02+00:00 hourly 0.9 https://trial.medpath.com/news/pathos-ai-names-iker-huerga-as-ceo-to-accelerate-ai-driven-oncology-drug-development 2025-05-08T16:35:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pathos-ai-names-iker-huerga-as-ceo-to-accelerate-ai-driven-oncology-drug-development 2025-05-08T16:35:26+00:00 hourly 0.9 https://trial.medpath.com/news/vivopower-advances-in-180-million-takeover-deal-with-energi-holdings-as-phase-i-due-diligence-completes 2025-05-08T16:35:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vivopower-advances-in-180-million-takeover-deal-with-energi-holdings-as-phase-i-due-diligence-completes 2025-05-08T16:35:20+00:00 hourly 0.9 https://trial.medpath.com/news/ss-innovations-to-seek-fda-approval-for-ssi-mantra-3-surgical-robotic-system 2025-05-08T16:35:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ss-innovations-to-seek-fda-approval-for-ssi-mantra-3-surgical-robotic-system 2025-05-08T16:35:04+00:00 hourly 0.9 https://trial.medpath.com/news/nanoviricides-broad-spectrum-antiviral-nv-387-advances-to-phase-ii-trials-for-mpox-treatment 2025-05-08T16:34:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nanoviricides-broad-spectrum-antiviral-nv-387-advances-to-phase-ii-trials-for-mpox-treatment 2025-05-08T16:34:50+00:00 hourly 0.9 https://trial.medpath.com/news/prime-medicine-advances-gene-editing-pipeline-with-key-programs-for-cgd-wilson-s-disease-and-aatd 2025-05-08T14:34:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prime-medicine-advances-gene-editing-pipeline-with-key-programs-for-cgd-wilson-s-disease-and-aatd 2025-05-08T14:34:23+00:00 hourly 0.9 https://trial.medpath.com/news/vectory-therapeutics-unveils-promising-preclinical-data-for-novel-als-treatment-targeting-oxidized-phospholipids 2025-05-08T14:33:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vectory-therapeutics-unveils-promising-preclinical-data-for-novel-als-treatment-targeting-oxidized-phospholipids 2025-05-08T14:33:49+00:00 hourly 0.9 https://trial.medpath.com/news/eminent-spine-receives-fda-510-k-clearance-for-world-s-first-3d-printed-titanium-pedicle-screw-system 2025-05-08T14:06:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eminent-spine-receives-fda-510-k-clearance-for-world-s-first-3d-printed-titanium-pedicle-screw-system 2025-05-08T14:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/viatris-reports-positive-phase-3-results-for-novel-fast-acting-meloxicam-in-acute-pain-treatment 2025-05-08T13:34:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/viatris-reports-positive-phase-3-results-for-novel-fast-acting-meloxicam-in-acute-pain-treatment 2025-05-08T13:34:14+00:00 hourly 0.9 https://trial.medpath.com/news/viatris-reports-positive-phase-3-results-for-xulane-lo-low-dose-contraceptive-patch 2025-05-08T13:34:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/viatris-reports-positive-phase-3-results-for-xulane-lo-low-dose-contraceptive-patch 2025-05-08T13:34:09+00:00 hourly 0.9 https://trial.medpath.com/news/johns-hopkins-study-links-hypoglycemia-to-diabetic-retinopathy-progression-experimental-drug-shows-promise 2025-05-08T13:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johns-hopkins-study-links-hypoglycemia-to-diabetic-retinopathy-progression-experimental-drug-shows-promise 2025-05-08T13:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/aptevo-advances-apvo711-novel-bispecific-antibody-combining-pd-l1-checkpoint-inhibition-with-cd40-immune-activation 2025-05-08T12:45:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aptevo-advances-apvo711-novel-bispecific-antibody-combining-pd-l1-checkpoint-inhibition-with-cd40-immune-activation 2025-05-08T12:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/nalu-reports-94-response-rate-in-largest-real-world-study-of-peripheral-nerve-stimulation-device 2025-05-08T12:19:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nalu-reports-94-response-rate-in-largest-real-world-study-of-peripheral-nerve-stimulation-device 2025-05-08T12:19:06+00:00 hourly 0.9 https://trial.medpath.com/news/novel-antibody-plt012-targets-fat-metabolism-to-overcome-immunotherapy-resistance-in-cancer 2025-05-08T10:34:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-antibody-plt012-targets-fat-metabolism-to-overcome-immunotherapy-resistance-in-cancer 2025-05-08T10:34:08+00:00 hourly 0.9 https://trial.medpath.com/news/newlimit-secures-130m-series-b-to-advance-epigenetic-reprogramming-for-age-reversal 2025-05-08T08:09:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/newlimit-secures-130m-series-b-to-advance-epigenetic-reprogramming-for-age-reversal 2025-05-08T08:09:25+00:00 hourly 0.9 https://trial.medpath.com/news/lundbeck-presents-phase-ii-data-for-amlenetug-in-multiple-system-atrophy-at-international-congress 2025-05-08T07:35:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lundbeck-presents-phase-ii-data-for-amlenetug-in-multiple-system-atrophy-at-international-congress 2025-05-08T07:35:11+00:00 hourly 0.9 https://trial.medpath.com/news/jaguar-health-advances-canalevia-ca1-field-study-for-canine-cancer-treatment-as-company-pursues-full-fda-approval 2025-05-08T06:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jaguar-health-advances-canalevia-ca1-field-study-for-canine-cancer-treatment-as-company-pursues-full-fda-approval 2025-05-08T06:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/major-depressive-disorder-pipeline-advances-with-75-companies-developing-novel-therapies 2025-05-08T04:36:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/major-depressive-disorder-pipeline-advances-with-75-companies-developing-novel-therapies 2025-05-08T04:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-s-odac-to-review-four-cancer-drugs-in-may-meeting 2025-05-08T04:34:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-s-odac-to-review-four-cancer-drugs-in-may-meeting 2025-05-08T04:34:32+00:00 hourly 0.9 https://trial.medpath.com/news/algorae-pharmaceuticals-partners-with-peter-maccallum-cancer-centre-to-validate-ai-predicted-drug-combinations 2025-05-08T04:34:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/algorae-pharmaceuticals-partners-with-peter-maccallum-cancer-centre-to-validate-ai-predicted-drug-combinations 2025-05-08T04:34:26+00:00 hourly 0.9 https://trial.medpath.com/news/rett-syndrome-pipeline-analysis-reveals-20-companies-developing-novel-therapeutics-with-gene-therapy-leading-innovation 2025-05-08T04:27:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rett-syndrome-pipeline-analysis-reveals-20-companies-developing-novel-therapeutics-with-gene-therapy-leading-innovation 2025-05-08T04:27:00+00:00 hourly 0.9 https://trial.medpath.com/news/new-report-reveals-promising-pipeline-for-autism-therapeutics-in-2025 2025-05-08T04:25:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-report-reveals-promising-pipeline-for-autism-therapeutics-in-2025 2025-05-08T04:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/bioaffinity-technologies-secures-3-25-million-in-funding-to-advance-early-cancer-detection-technology 2025-05-08T02:34:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioaffinity-technologies-secures-3-25-million-in-funding-to-advance-early-cancer-detection-technology 2025-05-08T02:34:27+00:00 hourly 0.9 https://trial.medpath.com/news/china-s-rising-influence-in-global-drug-development-bridging-studies-transform-us-clinical-research 2025-05-08T02:33:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-s-rising-influence-in-global-drug-development-bridging-studies-transform-us-clinical-research 2025-05-08T02:33:55+00:00 hourly 0.9 https://trial.medpath.com/news/crispr-therapeutics-casgevy-shows-commercial-progress-as-gene-therapy-pipeline-advances 2025-05-08T01:35:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crispr-therapeutics-casgevy-shows-commercial-progress-as-gene-therapy-pipeline-advances 2025-05-08T01:35:01+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-jr-446-for-rare-neurological-disorder-mps-iiib 2025-05-08T01:34:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-orphan-drug-designation-to-jr-446-for-rare-neurological-disorder-mps-iiib 2025-05-08T01:34:59+00:00 hourly 0.9 https://trial.medpath.com/news/india-s-cdsco-releases-draft-guidelines-for-biosimilars-approval-with-focus-on-advanced-analytical-methods 2025-05-08T01:34:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/india-s-cdsco-releases-draft-guidelines-for-biosimilars-approval-with-focus-on-advanced-analytical-methods 2025-05-08T01:34:45+00:00 hourly 0.9 https://trial.medpath.com/news/shionogi-to-acquire-japan-tobacco-s-pharma-units-for-1-1-billion 2025-05-08T01:34:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shionogi-to-acquire-japan-tobacco-s-pharma-units-for-1-1-billion 2025-05-08T01:34:15+00:00 hourly 0.9 https://trial.medpath.com/news/texas-proposes-25-million-for-first-fda-approved-ibogaine-clinical-trials-for-ptsd-and-addiction 2025-05-08T01:34:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/texas-proposes-25-million-for-first-fda-approved-ibogaine-clinical-trials-for-ptsd-and-addiction 2025-05-08T01:34:11+00:00 hourly 0.9 https://trial.medpath.com/news/vertex-pharmaceuticals-abandons-aav-vector-technology-amid-broader-industry-retreat-from-gene-therapy 2025-05-08T01:33:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vertex-pharmaceuticals-abandons-aav-vector-technology-amid-broader-industry-retreat-from-gene-therapy 2025-05-08T01:33:50+00:00 hourly 0.9 https://trial.medpath.com/news/atrasentan-receives-fda-accelerated-approval-for-iga-nephropathy-after-decades-long-development-journey 2025-05-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/atrasentan-receives-fda-accelerated-approval-for-iga-nephropathy-after-decades-long-development-journey 2025-05-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/federal-circuit-ruling-limits-patent-protection-for-machine-learning-applications-highlights-trade-secret-alternative 2025-05-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-circuit-ruling-limits-patent-protection-for-machine-learning-applications-highlights-trade-secret-alternative 2025-05-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/emerald-trial-data-reveals-duration-of-prior-cdk4-6-inhibitor-therapy-as-key-predictor-for-elacestrant-success-in-esr1-mutant-breast-cancer 2025-05-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/emerald-trial-data-reveals-duration-of-prior-cdk4-6-inhibitor-therapy-as-key-predictor-for-elacestrant-success-in-esr1-mutant-breast-cancer 2025-05-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ratio-therapeutics-to-build-65000-sq-ft-radiopharmaceutical-manufacturing-facility-in-salt-lake-city 2025-05-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ratio-therapeutics-to-build-65000-sq-ft-radiopharmaceutical-manufacturing-facility-in-salt-lake-city 2025-05-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/brexit-threatens-european-medicine-supply-chain-over-45-million-patient-packs-at-risk-monthly 2025-05-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brexit-threatens-european-medicine-supply-chain-over-45-million-patient-packs-at-risk-monthly 2025-05-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/phase-iii-clinical-trials-reveal-advances-in-non-infectious-uveitis-treatment-options 2025-05-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-iii-clinical-trials-reveal-advances-in-non-infectious-uveitis-treatment-options 2025-05-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ema-issues-updated-guidance-on-non-mutagenic-impurity-qualification-to-reduce-animal-testing 2025-05-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-issues-updated-guidance-on-non-mutagenic-impurity-qualification-to-reduce-animal-testing 2025-05-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/hazer-and-kbr-form-strategic-alliance-to-commercialize-low-emission-hydrogen-technology 2025-05-07T22:34:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hazer-and-kbr-form-strategic-alliance-to-commercialize-low-emission-hydrogen-technology 2025-05-07T22:34:48+00:00 hourly 0.9 https://trial.medpath.com/news/myriad-genetics-riskscore-study-shows-improved-breast-cancer-screening-personalization 2025-05-07T22:34:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/myriad-genetics-riskscore-study-shows-improved-breast-cancer-screening-personalization 2025-05-07T22:34:12+00:00 hourly 0.9 https://trial.medpath.com/news/fda-partners-with-openai-to-accelerate-drug-approval-process-with-ai 2025-05-07T22:33:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-partners-with-openai-to-accelerate-drug-approval-process-with-ai 2025-05-07T22:33:57+00:00 hourly 0.9 https://trial.medpath.com/news/bausch-lomb-secures-ce-mark-approval-for-luxlife-full-range-of-vision-intraocular-lens-in-europe 2025-05-07T19:34:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bausch-lomb-secures-ce-mark-approval-for-luxlife-full-range-of-vision-intraocular-lens-in-europe 2025-05-07T19:34:59+00:00 hourly 0.9 https://trial.medpath.com/news/ema-suspends-valneva-s-ixchiq-chikungunya-vaccine-for-elderly-following-safety-concerns 2025-05-07T19:34:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-suspends-valneva-s-ixchiq-chikungunya-vaccine-for-elderly-following-safety-concerns 2025-05-07T19:34:29+00:00 hourly 0.9 https://trial.medpath.com/news/ribbon-bio-strengthens-commercial-leadership-with-jeff-fitzgerald-appointment-as-global-sales-head-amid-mirosynthtm-dna-launch 2025-05-07T17:09:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ribbon-bio-strengthens-commercial-leadership-with-jeff-fitzgerald-appointment-as-global-sales-head-amid-mirosynthtm-dna-launch 2025-05-07T17:09:41+00:00 hourly 0.9 https://trial.medpath.com/news/pasithea-therapeutics-raises-6-3-million-to-advance-mek-inhibitor-for-neurofibromatosis-type-1 2025-05-07T17:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pasithea-therapeutics-raises-6-3-million-to-advance-mek-inhibitor-for-neurofibromatosis-type-1 2025-05-07T17:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/dcgi-launches-investigation-into-58-alleged-illegal-clinical-trials-at-vs-hospital-following-supreme-court-intervention 2025-05-07T16:48:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dcgi-launches-investigation-into-58-alleged-illegal-clinical-trials-at-vs-hospital-following-supreme-court-intervention 2025-05-07T16:48:00+00:00 hourly 0.9 https://trial.medpath.com/news/natera-s-prospera-heart-test-with-dqs-shows-superior-performance-in-detecting-transplant-rejection 2025-05-07T16:37:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/natera-s-prospera-heart-test-with-dqs-shows-superior-performance-in-detecting-transplant-rejection 2025-05-07T16:37:18+00:00 hourly 0.9 https://trial.medpath.com/news/ribbon-bio-launches-mirosynthtm-dna-platform-to-advance-complex-synthetic-dna-production 2025-05-07T16:34:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ribbon-bio-launches-mirosynthtm-dna-platform-to-advance-complex-synthetic-dna-production 2025-05-07T16:34:40+00:00 hourly 0.9 https://trial.medpath.com/news/gates-foundation-awards-evotec-2-5m-grant-to-advance-next-generation-tuberculosis-treatments 2025-05-07T16:34:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gates-foundation-awards-evotec-2-5m-grant-to-advance-next-generation-tuberculosis-treatments 2025-05-07T16:34:26+00:00 hourly 0.9 https://trial.medpath.com/news/tuhura-biosciences-initiates-phase-1b-2a-trial-of-ifx-hu2-0-for-deep-seated-merkel-cell-carcinoma 2025-05-07T16:34:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tuhura-biosciences-initiates-phase-1b-2a-trial-of-ifx-hu2-0-for-deep-seated-merkel-cell-carcinoma 2025-05-07T16:34:14+00:00 hourly 0.9 https://trial.medpath.com/news/immunewalk-s-iw-601-shows-positive-phase-1-results-in-novel-monocyte-targeting-approach-for-inflammatory-diseases 2025-05-07T13:55:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunewalk-s-iw-601-shows-positive-phase-1-results-in-novel-monocyte-targeting-approach-for-inflammatory-diseases 2025-05-07T13:55:00+00:00 hourly 0.9 https://trial.medpath.com/news/vigil-neuroscience-advances-dual-trem2-programs-with-promising-results-for-neurodegenerative-diseases 2025-05-07T13:36:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vigil-neuroscience-advances-dual-trem2-programs-with-promising-results-for-neurodegenerative-diseases 2025-05-07T13:36:18+00:00 hourly 0.9 https://trial.medpath.com/news/shionogi-receives-regulatory-clearance-for-torii-pharmaceutical-acquisition-tender-offer-proceeds 2025-05-07T13:36:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shionogi-receives-regulatory-clearance-for-torii-pharmaceutical-acquisition-tender-offer-proceeds 2025-05-07T13:36:10+00:00 hourly 0.9 https://trial.medpath.com/news/arkbio-s-ak3280-shows-promising-results-in-phase-ii-ipf-trial-with-significant-lung-function-improvement 2025-05-07T13:35:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arkbio-s-ak3280-shows-promising-results-in-phase-ii-ipf-trial-with-significant-lung-function-improvement 2025-05-07T13:35:45+00:00 hourly 0.9 https://trial.medpath.com/news/isarna-s-isth0036-shows-promise-in-reducing-retinal-fibrosis-in-phase-2-better-trial 2025-05-07T13:35:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/isarna-s-isth0036-shows-promise-in-reducing-retinal-fibrosis-in-phase-2-better-trial 2025-05-07T13:35:06+00:00 hourly 0.9 https://trial.medpath.com/news/nefecon-receives-full-nmpa-approval-for-iga-nephropathy-treatment-in-china-removing-proteinuria-restrictions 2025-05-07T13:34:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nefecon-receives-full-nmpa-approval-for-iga-nephropathy-treatment-in-china-removing-proteinuria-restrictions 2025-05-07T13:34:14+00:00 hourly 0.9 https://trial.medpath.com/news/corvista-health-validates-non-invasive-pulmonary-hypertension-diagnostic-system-in-major-clinical-study 2025-05-07T12:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/corvista-health-validates-non-invasive-pulmonary-hypertension-diagnostic-system-in-major-clinical-study 2025-05-07T12:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/european-feder-grant-awarded-to-leo-cancer-care-and-centre-leon-berard-for-upright-radiation-therapy-innovation 2025-05-07T11:04:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/european-feder-grant-awarded-to-leo-cancer-care-and-centre-leon-berard-for-upright-radiation-therapy-innovation 2025-05-07T11:04:30+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-discovery-pla2g15-identified-as-novel-target-for-neurometabolic-disorders 2025-05-07T11:02:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-discovery-pla2g15-identified-as-novel-target-for-neurometabolic-disorders 2025-05-07T11:02:00+00:00 hourly 0.9 https://trial.medpath.com/news/aboleris-pharma-initiates-first-in-human-trial-of-novel-anti-cd45rc-antibody-for-rheumatoid-arthritis 2025-05-07T10:35:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aboleris-pharma-initiates-first-in-human-trial-of-novel-anti-cd45rc-antibody-for-rheumatoid-arthritis 2025-05-07T10:35:32+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-in-primary-sclerosing-cholangitis-dr-falk-pharma-s-norucholic-acid-shows-positive-phase-3-results 2025-05-07T10:35:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-in-primary-sclerosing-cholangitis-dr-falk-pharma-s-norucholic-acid-shows-positive-phase-3-results 2025-05-07T10:35:29+00:00 hourly 0.9 https://trial.medpath.com/news/bulevirtide-shows-durable-response-in-chronic-hepatitis-delta-virus-after-treatment-cessation 2025-05-07T10:34:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bulevirtide-shows-durable-response-in-chronic-hepatitis-delta-virus-after-treatment-cessation 2025-05-07T10:34:22+00:00 hourly 0.9 https://trial.medpath.com/news/astraveus-partners-with-necstgen-to-revolutionize-car-t-manufacturing-with-microfluidic-technology 2025-05-07T10:34:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astraveus-partners-with-necstgen-to-revolutionize-car-t-manufacturing-with-microfluidic-technology 2025-05-07T10:34:19+00:00 hourly 0.9 https://trial.medpath.com/news/chop-researchers-propose-alk-inhibitors-as-new-standard-for-hereditary-neuroblastoma 2025-05-07T10:34:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chop-researchers-propose-alk-inhibitors-as-new-standard-for-hereditary-neuroblastoma 2025-05-07T10:34:16+00:00 hourly 0.9 https://trial.medpath.com/news/gemvax-s-gv1001-receives-fda-fast-track-designation-and-korean-therapeutic-use-approval-for-progressive-supranuclear-palsy 2025-05-07T10:34:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gemvax-s-gv1001-receives-fda-fast-track-designation-and-korean-therapeutic-use-approval-for-progressive-supranuclear-palsy 2025-05-07T10:34:11+00:00 hourly 0.9 https://trial.medpath.com/news/marea-s-mar-001-shows-promising-lipid-lowering-results-in-phase-2a-cardiovascular-study 2025-05-07T10:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/marea-s-mar-001-shows-promising-lipid-lowering-results-in-phase-2a-cardiovascular-study 2025-05-07T10:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/markel-launches-global-clinical-trials-insurance-solution-to-accelerate-research-timelines 2025-05-07T09:39:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/markel-launches-global-clinical-trials-insurance-solution-to-accelerate-research-timelines 2025-05-07T09:39:00+00:00 hourly 0.9 https://trial.medpath.com/news/fastwave-medical-receives-irb-approval-for-novel-coronary-laser-intravascular-lithotripsy-system 2025-05-07T08:41:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fastwave-medical-receives-irb-approval-for-novel-coronary-laser-intravascular-lithotripsy-system 2025-05-07T08:41:00+00:00 hourly 0.9 https://trial.medpath.com/news/shingles-vaccine-reduces-cardiovascular-risk-by-23-for-up-to-eight-years-study-finds 2025-05-07T07:34:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shingles-vaccine-reduces-cardiovascular-risk-by-23-for-up-to-eight-years-study-finds 2025-05-07T07:34:52+00:00 hourly 0.9 https://trial.medpath.com/news/beacon-therapeutics-reports-promising-phase-2-data-for-gene-therapy-in-x-linked-retinitis-pigmentosa 2025-05-07T07:34:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beacon-therapeutics-reports-promising-phase-2-data-for-gene-therapy-in-x-linked-retinitis-pigmentosa 2025-05-07T07:34:42+00:00 hourly 0.9 https://trial.medpath.com/news/vinay-prasad-s-appointment-to-lead-fda-s-cber-signals-potential-shift-in-regulatory-standards 2025-05-07T07:34:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vinay-prasad-s-appointment-to-lead-fda-s-cber-signals-potential-shift-in-regulatory-standards 2025-05-07T07:34:00+00:00 hourly 0.9 https://trial.medpath.com/news/roche-launches-elecsys-pro-c3-test-for-precise-liver-fibrosis-assessment-in-masld-patients 2025-05-07T07:33:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-launches-elecsys-pro-c3-test-for-precise-liver-fibrosis-assessment-in-masld-patients 2025-05-07T07:33:57+00:00 hourly 0.9 https://trial.medpath.com/news/genenta-science-partners-with-anemocyte-to-advance-cell-based-cancer-therapy-manufacturing 2025-05-07T07:17:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genenta-science-partners-with-anemocyte-to-advance-cell-based-cancer-therapy-manufacturing 2025-05-07T07:17:00+00:00 hourly 0.9 https://trial.medpath.com/news/annexon-to-present-promising-data-on-anx007-s-neuroprotective-effects-in-geographic-atrophy-at-major-ophthalmology-conferences 2025-05-07T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/annexon-to-present-promising-data-on-anx007-s-neuroprotective-effects-in-geographic-atrophy-at-major-ophthalmology-conferences 2025-05-07T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/e-therapeutics-etx-312-shows-promise-as-disease-modifying-mash-treatment-in-preclinical-studies 2025-05-07T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/e-therapeutics-etx-312-shows-promise-as-disease-modifying-mash-treatment-in-preclinical-studies 2025-05-07T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/koala-health-raises-20-million-series-b-to-transform-pet-medication-delivery-platform 2025-05-07T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/koala-health-raises-20-million-series-b-to-transform-pet-medication-delivery-platform 2025-05-07T05:00:00+00:00 hourly 0.9